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ABBREVIATIONS
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COS-1 cells African green monkey kidney cells
CSTA cystatin A
CSTB / CSTB human cystatin B gene / protein
Cstb / Cstb mouse cystatin B gene / protein
CSTB2 / CSTB2 human cystatin B 2 splice variant transcript / protein
Cstb2 / Cstb2 mouse cystatin B 2 splice variant transcript / protein
CST3 / CSTC cystatin C gene / protein
CTSB cathepsin B
CTSD cathepsin D
CTSK cathepsin K
CTSL cathepsin L
CTSS cathepsin S
del deletion
DNA deoxyribonucleic acid
DRPLA dentatorubral-pallidoluysian atrophy
E embryonic day
ELISA enzyme-linked immunosorbent assay
EPM1 progressive myoclonus epilepsy of Unverricht-Lundborg type
EPM1B Unverricht-Lundborg disease locus B
EPM2 Lafora disease
EST expressed sequence tag
fs frameshift
HGP human genome project
IVT in vitro translation
kb kilobase, 1 000 bp
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kDa kiloDalton
LAMP-1 lysosome-associated membrane protein 1
LD Lafora disease
MHC major histocompatibility complex
MPR mannose-6-phosphate receptor
mRNA messenger RNA
mSec13 mammalian secretory protein 13
mtDNA mitochondrial DNA
NCL neuronal ceroid lipofuscinosis
OMIM Online Mendelian Inheritance in Man
p short arm of a chromosome
P postnatal day
p. protein reference sequence
PCR polymerase chain reaction
PDI protein disulfide isomerase
PME progressive myoclonus epilepsy
q long arm of a chromosome
RNA ribonucleic acid
RT-PCR reverse transcriptase PCR
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
Sp1 specificity protein 1
TGN46 trans-Golgi network protein 46
ULD Unverricht-Lundborg disease
UTR untranslated region
In addition, standard one-letter abbreviations of nucleic acids and amino acids as well as
three-letter abbreviations of amino acids are used.
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ABSTRACT
Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) is an
autosomal recessively inherited disorder characterized by stimulus-sensitive
myoclonus, tonic-clonic epileptic seizures, age of onset at 6-15 years and a
progressive course. Mutations in the cystatin B (CSTB) gene underlie EPM1. The
most common underlying mutation is a dodecamer repeat expansion in the putative
promoter region of the gene. In addition, prior to this work, seven other EPM1-
associated CSTB mutations had been published. CSTB, a cysteine protease inhibitor,
is a ubiquitously expressed tightly binding reversible inhibitor of cathepsins B, L, H
and S, but its physiological function is unknown. In this study, we characterized the
regulation and expression of the CSTB gene, determined the subcellular localization
of the CSTB protein and elucidated the consequences of patient mutations on
expression and subcellular localization of the CSTB gene and protein.
Two novel EPM1-associated CSTB mutations, c.149G>A and c.168+1_18del
were identified.
Using promoter-luciferase reporter gene constructs, the basal CSTB promoter
activity was located in the region from -670 to -1 bp from the translation initiation
codon. The binding activity of transcription factors to five Sp1 and four AP1 sites as
well as weak binding to an androgen response element (ARE) half site was
demonstrated.
The mouse Cstb transcript was present in all embryonic stages and adult
tissues examined, the expression being highest at embryonic day 7. In adult tissues
highest expression was detected in thymus. In sectioned E17 embryos highest
expression was seen in the thymus, intestine and neopallial cortex. In postnatal brain
Cstb expression was cell-specific, being highest in the cortex, caudate putamen,
thalamus and hippocampus, as well as in the Purkinje cell layer of the cerebellum.
Cystatin B expression thus seems to be tightly temporally and spatially regulated.
Several alternatively spliced CSTB isoforms were identified, of these CSTB2
was widely expressed, also in brain, but with very low levels compared to CSTB
expression. The other splice variants showed more restricted tissue expression.
The endogenous CSTB protein localized to the nucleus, cytoplasm and
lysosomes in COS-1 cells and human myoblasts. When myoblasts were differentiated
into myotubes CSTB was excluded from the nucleus and lysosomes and merely
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localized to the cytoplasm, suggesting that the subcellular distribution of CSTB is
dependent on the differentation status of the cells.
Compatible with some 10-fold lowered in vitro transcriptional activity of the
CSTB promoter containing a “premutation” length dodocamer repeat expansion, the
CSTB expression was clearly decreased in individuals with “premutation” repeat
expansions. The expression of CSTB mRNA and CSTB protein was markedly reduced
in cells of EPM1 patients irrespective of the mutation type with the exception of one
missense mutation. The proteins representing patient missense mutations were
localized to cytoplasm and nucleus, but failed to associate with lysosomes, implying
the importance of the lysosomal association for the proper physiological function of
CSTB.
By quantitative real-time PCR the splice variant CSTB2 was shown to be
expressed at very low levels in all tissues. Whether CSTB2 protein is translated in
vivo and its physiological relevance remain unknown. In patients the level of CSTB2
expression was reduced similarly to that of CSTB . We were unable to detect
endogenous CSTB2 protein in cell lines with the antibodies available. The
overexpressed wild-type and p.Gly4Arg mutant CSTB2 proteins localized evenly to
cytoplasm and nucleus, but not to lysosomes. Instead, the p.Gly50Glu CSTB2 protein
aggregated in cytoplasm and nucleus.
The data produced in this study lay the basis for further understanding of the
role of CSTB in health and disease.
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INTRODUCTION
The human genome project (HGP), initiated formally in 1990, published the initial
sequence of the 3 billion base pair human genome in 2001 by the publicly sponsored
HGP (Lander et al., 2001b) and by the private company, Celera Genomics (Venter et
al., 2001). The complete and high-quality sequence was reached in 2003, 50 years
after the discovery of the structure of DNA (Watson and Crick, 1953). The most
unexpected result of the HGP was that the estimated number of protein-coding genes
in the human genome was reduced from an estimated 50000-100000 to only 20000-
25000 genes (International Human Genome Sequencing Consortium, 2004), which
lead to the realization that much of the diversity seen in higher vertebrates has to be
generated by other mechanisms such as alternative splicing, post-translational
modifications and multifunctional proteins (Levine and Tjian, 2003; Pennisi, 2005).
In addition, the genomes of over one hundred eukaryotic model organisms have been
sequenced (http://www.ncbi.nlm.nih.gov/), including the chimpanzee Pan troglodytes
(Chimpanzee Sequencing and Analysis Consortium, 2005), the domestic dog Canis
familiaris (Lindblad-Toh et al., 2005), the mouse Mus musculus (Waterston et al.,
2002), the rat Rattus norvegicus (Gibbs et al., 2004), the fruitfly Drosophila
melanogaster  (Adams et al., 2000; Myers et al., 2000), the roundworm
Caenorhabditis elegans (C. elegans Sequencing Consortium, 1998) and the baker’s
yeast Saccharomyces cerevisiae (Goffeau et al., 1996).
The HGP has had an enormous impact on the identification of genes that are
associated with diseases. The Online Mendelian Inheritance in Man (OMIM) database
lists more than 2000 of those currently known (http://www.ncbi.nlm.nih.gov/). In
Finland, significant progress has been made especially in identifying the so-called
Finnish disease heritage genes. This term, introduced by Drs. Nevanlinna, Norio and
Perheentupa (Norio et al., 1973), refers to a collection of monogenic diseases that are
more prevalent in Finland than in other populations. To date, the Finnish disease
heritage is composed of 36 disorders (Norio, 2003), of which the disease gene has
been identified in 33, and the disease gene locus is known for an additional one. Most
of these diseases have an autosomal recessive mode of inheritance and one founder
mutation typically accounts for 70-100% of these disease alleles (http://www.findis.
org/).
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The progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) is
one of the diseases belonging to the Finnish disease heritage. The study presented in
this thesis is one part of a long-term research project aiming at understanding the
molecular pathogenesis of EPM1. Before this study the research group had identified
mutations in the underlying gene for EPM1 by positional cloning (Lehesjoki et al.,
1991; Lehesjoki et al., 1992; Lehesjoki et al., 1993; Pennacchio et al., 1996;
Virtaneva et al., 1996). The major mutation is an expansion of a dodecamer
minisatellite repeat in the putative promoter region of the CSTB gene (Lalioti et al.,
1997b). This mutation accounts for over 90% of the disease alleles (Virtaneva et al.,
1997) and is unique in that it represented the first case of instability of a repeat unit
other than trinucleotides associated with a human disease. The CSTB protein has been
identified and much studied in Finland (Rinne, 1981; Järvinen and Rinne, 1982; Rinne
et al., 2002; Laitala-Leinonen et al., 2006). CSTB, a cysteine protease inhibitor, is
widely expressed (Pennacchio et al., 1996) and binds in vitro to cathepsins B, H, L
and S (Green et al., 1984). This study was performed to investigate CSTB gene
expression and CSTB protein functions in normal and pathological conditions.
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REVIEW OF THE LITERATURE
1. Epilepsy and genetics of epilepsy
Human epilepsy is one of the most common neurological conditions with an active
prevalence of 1% and a cumulative incidence by the age of 80 years of about 3%
(Bate and Gardiner, 1999). Around 60 million people worldwide are affected and
45000 individuals in Finland are on anti-epileptic medication. The term “epilepsy”
actually describes a very heterogeneous group of disorders characterized by
predisposition to seizures that have different causes, ages of onset, clinical
presentations and outcomes. The seizures themselves are the clinical outcome of
cortical dysfunction due to a sudden, abnormal, excessive, and disorganized discharge
of brain cells. Clinical manifestations include abnormal motor, sensory, cognitive,
psychic and/or autonomic phenomena. A diagnosis of epilepsy requires at least two
unprovoked seizures (Steinlein, 2004). The diagnostic scheme is divided into five
parts, ictal phenomenology, seizure type, syndrome, etiology and impairment, to
facilitate the clinical approach (Engel, 2001). Self-limited seizure types can be
divided into generalized and focal seizures. Generalized seizures can be subdivided
into e.g. tonic-clonic, clonic, myoclonic absence, tonic and myoclonic seizures. Focal
seizures are divided into e.g. focal sensory and motor seizures (http://ilae-
epilepsy.org/). The etiology of epilepsy can be symptomatic or idiopathic.
Symptomatic epilepsies are caused by e.g. strokes, head injuries, developmental
abnormalities, infections, presence of tumors or degenerative conditions. In idiopathic
epilepsies no obvious reason or any other neurological abnormalities are found, and
the origin is mainly genetic (Steinlein, 2004). All possible modes of inheritance are
found in epilepsies, including autosomal, X-chromosomal, mitochondrial, and
simple/Mendelian and complex inheritance. A genetic component has been estimated
to be present in 40% of all epilepsies (Annegers et al., 1996). The majority of
inherited epilepsies are believed to be multifactorial, with a contribution of several
susceptibility genes and environmental factors (Mulley et al., 2005). Of all inherited
epilepsies only a few have a known causative gene. These rare-monogenic epilepsies
involve mutations in genes which lead, for example, to abnormal ion-channel
conductance, deficits in energy or protein metabolism, or defects in cell migration.
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2. Progressive myoclonus epilepsies
The progressive myoclonus epilepsies (PMEs) belong to a group of symptomatic
epilepsies and are a heterogeneous group of inherited disorders characterized by
myoclonic and tonic-clonic seizures and progressive neurological deterioration
(Berkovic et al., 1986; Marseille Consensus Group, 1990).
PMEs are divided into five main diseases or disease groups: Unverricht-
Lundborg disease (ULD/EPM1), Lafora disease (LD/EPM2), neuronal ceroid
lipofuscinoses (NCLs), sialidoses, and myoclonic epilepsy with ragged-red fibers
(MERRF) (Marseille Consensus Group, 1990). In all of these genetic mutations have
been identified and account for the majority of PME cases. A summary of these
disease genes is presented in Table 1. Four of the five disease entities have an
autosomal recessive mode of inheritance while MERRF is maternally inherited in
mitochondrial DNA. In addition, a number of rare disorders can cause the PME
phenotype, for example the autosomal dominantly inherited dentatorubral-
pallidoluysian atrophy (DRPLA), most prevalent in Japan, characterized by ataxia,
myoclonus, choreoathetosis, epilepsy and dementia (Smith et al., 1958; Naito and
Oyanagi, 1982), and is caused by an expanded trinucleotide CAG repeat in the
DRPLA gene (Koide et al., 1994). Gaucher disease type III is characterized by ataxia,
spastic paraplegia, grand mal and/or psychomotor seizures, supranuclear
ophthalmoplegia and dementia, and is caused by mutations in the gene encoding acid
beta-glucosidase (GBA) (Tsuji et al., 1987).
Lafora disease shows onset of grand mal seizures and/or myoclonus around
the age of 15 years. Rapid and severe mental deterioration develops, often with
psychotic symptoms, culminating in continuous seizures and death less than 10 years
after onset. LD is histologically characterized with starch-like polyglucosan masses
known as Lafora bodies (Lafora and Gluck, 1911; Chan et al., 2005). LD has the same
kind of clinical manifestation as ULD, at least during the first years after onset, and
before the demarcation of those two disorders on clinical grounds by Norio and
Koskiniemi in 1979 there was confusion in their classification. The names of
Unverricht, Lundborg and Lafora were coupled and separated in every possible way.
Since in histological studies no Lafora bodies or Lafora-like deposits were found in
Finnish patients or Swedish patients with Finnish ancestry (Haltia et al., 1969;
Koskiniemi et al., 1974a), Norio and Koskiniemi proposed separate classifications for
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Unverricht-Lundborg and Lafora diseases, as well as distinguished the clinical
phenotypes from each other (Norio and Koskiniemi, 1979). Lafora disease can be
caused by mutations in genes encoding either laforin (EPM2A) (Minassian et al.,
1998; Serratosa et al., 1999), a protein composed of a carbohydrate binding domain
and a dual-specific phosphatase domain (Ganesh et al., 2000; Minassian et al., 2000;
Minassian et al., 2001; Chan et al., 2004a) or malin (NHLRC1 [NHL repeat
containing 1] or EPM2B) (Chan et al., 2003), a putative E3 ubiquitin ligase (Chan et
al., 2003). To date, a total of 43 different EPM2A and 40 EPM2B associated
mutations have been identified (http://projects.tcag.ca/lafora/; Ianzano et al., 2005). A
third gene locus for LD is speculated to exist (Chan et al., 2004b). Two Epm2a mouse
models have been created (Ganesh et al., 2002; Chan et al., 2004a). Interestingly, in
the canine Epm2b gene an expanded dodecamer repeat mutation (Lohi et al., 2005)
causes naturally occuring LD. The normal sequence of the 5’ half of the Epm2b
gene’s single exon consists of two consecutive identical dodecamers and a third copy
differing by a single nucleotide. The bi-allelic expansion mutation contains 19-26
copies of the dodecamer repeat and causes more than 900 times reduced mRNA levels
of Epm2b in the skeletal muscle of affected domestic dogs (Lohi et al., 2005).
The neuronal ceroid lipofuscinoses are clinically characterized by progressive
mental and motor retardation, epileptic seizures, myoclonus, visual failure and
premature death (Santavuori, 1988; Haltia, 2003). Histopathologically the diseases are
characterized by the accumulation of autofluorescent storage material in several cell
types, especially in neurons (Santavuori, 1988). The NCL disorders are divided
depending on the age of onset, the rate of progression, the morphology of the storage
material and the genetic basis into ten subgroups: infantile NCL (INCL/CLN1),
classical late-infantile NCL (cLINCL/CLN2), juvenile NCL (JNCL/CLN3), adult
NCL (CLN4), Finnish variant late-infantile NCL (vLINCLFin/CLN5), variant late-
infantile NCL (vLINCL/CLN6), Turkish variant late-infantile NCL
(vLINCLTurk/CLN7), Northern epilepsy (EPMR/CLN8) (Haltia, 2003), variant
juvenile NCL (CLN9) (Schulz et al., 2004) and congenital NCL (CLN10) (Siintola et
al., 2006). Seven causative genes have been identified, four of them encode soluble
lysosomal proteins and three transmembrane proteins. Genes encoding soluble
lysosomal proteins are palmitoyl protein thioesterase 1 (PPT1/CLN1) (Järvelä et al.,
1991; Vesa et al., 1995), tripeptidyl-peptidase I (TPPI/CLN2) (Sharp et al., 1997;
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Sleat et al., 1997), CLN5 (Klockars et al., 1996; Savukoski et al., 1998) and cathepsin
D (CTSD/CLN10) (Siintola et al., 2006; Steinfeld et al., 2006). Genes encoding
transmembrane proteins are CLN3 (Gardiner et al., 1990; International Batten Disease
Consortium, 1995), CLN6 (Sharp et al., 1997; Gao et al., 2002; Wheeler et al., 2002)
and CLN8 (Haltia et al., 1969; Ranta et al., 1999). CLN9 is a putative gene encoding a
protein with proposed function as a regulator of dihydroceramide synthase (Schulz et
al., 2004; Schulz et al., 2006). In Turkish vLINCL patients mutations in the CLN8
(Ranta et al., 2004) and CLN6 (Siintola et al., 2005) genes have been identified,
though the “true” vLINCLTurk gene, CLN7,  remains to be defined (Siintola et al.,
2005). Recently mutations have been identified in the CTSD gene causing both
congenital NCL (CLN10) (Siintola et al., 2006) and vLINCL (Steinfeld et al., 2006).
The NCL Mutation Database summarises approximately 160 mutations causing NCL
(http://www.ucl.ac.uk/ncl/). Targeted disruption of murine cathepsin F (Tang et al.,
2006), and chloride channels ClC-3 (Stobrawa et al., 2001; Yoshikawa et al., 2002),
ClC-6 (Poet et al., 2006) and ClC-7 (Kasper et al., 2005) have lead to NCL-like
phenotypes. Several natural NCL animal models exist, for example the CLN2 dog
(Awano et al., 2006a), CLN6 mouse (Gao et al., 2002; Wheeler et al., 2002), CLN8
mouse (Ranta et al., 1999) and dog (Katz et al., 2005), and CTSD sheep (Tyynelä et
al., 2000) and dog (Awano et al., 2006b). In addition, several NCL mouse models
have been created (Saftig et al., 1995; Bronson et al., 1998; Katz et al., 1999;
Mitchison et al., 1999; Gupta et al., 2001; Cotman et al., 2002; Kopra et al., 2004;
Sleat et al., 2004; Jalanko et al., 2005).
Sialidoses, characterized by the progressive lysosomal storage of sialidated
glycopeptides and oligosaccharides, are caused by mutations in the gene encoding
neuraminidase 1 (NEU1) (Bonten et al., 1996; Seyrantepe et al., 2003). Mutations in
NEU1 can cause both mild (type I) and severe (type II) disease phenotypes, depending
on the residual activity of the mutated enzyme. Type I sialidosis occurs in the second
decade of life and results in progressive loss of vision associated with nystagmus,
ataxia, myoclonus and grand mal seizures. Type II sialidosis is characterized by the
presence of abnormal somatic features and is divided into congenital, infantile and
juvenile subtypes. The sialidosis mouse model has been generated by targeted
disruption of the Neu1 locus (de Geest et al., 2002).
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Myoclonic epilepsy associated with ragged-red fibers is a maternally inherited
disease characterized by myoclonic epilepsy and ragged-red fibres in the muscle. In
addition, myoclonus, dementia, cardiomyopathy, pyramidal tract signs, neuropathy,
optic nerve atrophy and neurosensory hearing loss are often present (Fukuhara et al.,
1980; Rosing et al., 1985). The mutations in mitochondrial genes tRNALys (TRNK)
(Shoffner et al., 1990) and tRNAPhe (TRNF) (Mancuso et al., 2004) affect the
translation of all mtDNA-encoded genes and produce multiple deficiencies in the
enzyme complexes of the respiratory chain, most prominently complex I (NADH-
CoQ reductase) and complex IV (cytochrome-c oxidase) (Wallace et al., 1988;
Bindoff et al., 1991).
In Lafora disease, NCLs and sialidoses the cellular mechanism of
pathogenesis appear to be similar, with progressive formation of intracellular
inclusion bodies (Harriman et al., 1955; Zeman and Albert, 1963; Carpenter et al.,
1974; O'Brien, 1977). In MERRF abnormal mitochondrial proliferation, cytochrome-c
oxidase (COX)-negative fibers and ragged-red fibers are detected (Nakamura et al.,
1995; Mancuso et al., 2004; Melone et al., 2004). In contrast, EPM1 is not associated
with inclusion bodies, storage material or mitochondrial defects (Lehesjoki and
Koskiniemi, 1998; Pennacchio et al., 1998).
Table 1. The main human PME genes.
DISEASE LOCUS CHROMOSOMAL
LOCALIZATION
GENE REFERENCE
Unverricht-Lundborg
disease
EPM1
EPM1B
21q22.3
12p11-q13
CSTB
?
(Pennacchio et al., 1996)
(Berkovic et al., 2005)
Lafora disease EPM2A
EPM2B
EPM2C
6q24
6p22.3
?
EPM2A
EPM2B
?
(Minassian et al., 1998; Serratosa et al., 1999)
(Chan et al., 2003)
Neuronal ceroid
lipofuscinoses
CLN1
CLN2
CLN3
CLN4 (putative)
CLN5
CLN6
CLN7
CLN8
CLN9
CLN10
1p32
11p15
16p12.1
?
13q22.1-q32
15q23
?
8p23
?
11p15.5
PPT1
TPP1
CLN3
?
CLN5
CLN6
?
CLN8
?
CTSD
(Vesa et al., 1995)
(Sleat et al., 1997)
(IBDC*, 1995)
(Savukoski et al., 1998)
(Gao et al., 2002)
(Ranta et al., 1999)
(Siintola et al., 2006; Steinfeld et al., 2006)
Sialidoses type I and II NEU1 6p21.3 NEU1 (Bonten et al., 1996)
Myoclonic epilepsy with
ragged-red fibers
TRNK
TRNF
mtDNA
mtDNA
TRNK
TRNF
(Shoffner et al., 1990)
(Mancuso et al., 2004)
*International Batten Disease Consortium.
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3. Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1)
Unverricht-Lundborg disease was first described by Heinrich Unverricht in Estonia
(Unverricht, 1891; Unverricht, 1895) and by Herman Lundborg in Sweden
(Lundborg, 1903; Lundborg, 1912; Lundborg, 1913). Progressive myoclonus epilepsy
of Unverricht-Lundborg type (EPM1; OMIM #254800; also known as Baltic or
Mediterranean myoclonus epilepsy) is the single most common cause of progressive
myoclonus epilepsy worldwide (Marseille Consensus Group, 1990). EPM1 is most
prevalent in Finland and it belongs to the Finnish Disease Heritage (Norio, 2003).
EPM1 is autosomal recessively inherited and the incidence in Finland is 1 in 20000
births (Norio and Koskiniemi, 1979; Eldridge et al., 1983; http://www.findis.org/),
meaning around three to four new patient diagnoses per year. At present there are
approximately 200 patients known in Finland (Lehesjoki and Koskiniemi, 1999;
http://www.findis.org/). EPM1 is also prevalent in the Mediterranean region
(Marseille Consensus Group, 1990; Malafosse et al., 1992; Lehesjoki et al., 1994;
Parmeggiani et al., 1997) and is also found around the world (Eldridge et al., 1983;
Marseille Consensus Group, 1990).
3. 1. Clinical symptoms
The onset of symptoms occurs between 6-15 years of age with myoclonus and/or
generalized tonic-clonic epileptic seizures (Koskiniemi et al., 1974a). Stimulus-
sensitive myoclonus is an essential feature for the diagnosis and the first symptom in
approximately half of the patients (Norio and Koskiniemi, 1979; Koskiniemi, 1986;
Koskiniemi, 1987). Myoclonus (brief contraction of a muscle or group of muscles)
occurs spontaneously, or in association with action or external stimuli such as light,
noise or touch (Berkovic et al., 1986; Marseille Consensus Group, 1990). Myoclonus
may be focal or multifocal and may generalize to a shaking attack, to a tonic-clonic
seizure attack and unconsciousness. The generalized tonic-clonic epileptic seizures
are most frequent 3-7 years after the disease onset and may later, with anticonvulsive
medication, cease entirely (Koskiniemi et al., 1974a; Norio and Koskiniemi, 1979;
Koskiniemi, 1986). The clinical course of the disease progresses slowly, with ataxia,
intentional tremor, incoordination and dysarthria manifesting later. No major
intellectual decline is present, but a slow decrease in the IQ of about 10 points in a
decade has been reported (Koskiniemi, 1974; Koskiniemi et al., 1974a; Koskiniemi,
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1986). In addition, depression and emotional lability are often observed (Lehesjoki
and Koskiniemi, 1999). Electroencephalogram (EEG) is abnormal even before the
symptoms appear (Koskiniemi et al., 1974b; Lehesjoki and Koskiniemi, 1998) with
typical spike-wave or polyspike-wave discharges (Koskiniemi et al., 1974b;
Koskiniemi, 1986). Sodium valproate alone or combined with clonazepam or
piracetam is the most effective therapy (Iivanainen and Himberg, 1982; Somerville
and Olanow, 1982; Koskiniemi, 1986; Koskiniemi et al., 1998), whereas the
previously used phenytoin is considered harmful due to toxic side effects (Eldridge et
al., 1983). At present due to better medication and improvement in the whole therapy
regimen the life span of EPM1 patients is probably normal (Lehesjoki, 2002).
3. 2. Histopathology
On histopathological examinations of the brain, widespread non-specific degenerative
changes and loss of Purkinje cells in the cerebellum have been observed (Haltia et al.,
1969; Koskiniemi et al., 1974a; Eldridge et al., 1983). Cerebellar atrophy and gliosis
are present as well. Neuronal degenerative changes have been observed for example
in cerebral cortex, striatum, medial and reticular thalamus, brainstem nuclei and spinal
cord. In addition, proliferation of Bergmann glia has been detected. However, some of
these changes detected in the patients may have resulted from treatment with
phenytoin. Furthermore, no intracellular inclusion bodies or storage material have
been observed (Haltia et al., 1969; Koskiniemi et al., 1974a; Eldridge et al., 1983).
3. 3. Molecular genetics
The mutated gene responsible for EPM1 was identified using a positional cloning
approach. A genome-wide search for linkage localized the EPM1 gene to
chromosome 21q22.3 (Lehesjoki et al., 1991). By linkage disequilibrium analysis and
exploiting the historical recombinations in haplotype analyses the localization was
narrowed to an approximately 175 kb region (Virtaneva et al., 1996). A systematic
search for genes in this region resulted in identification of a gene encoding a
previously described but unmapped protein, cystatin B (CSTB), a cysteine protease
inhibitor (Pennacchio et al., 1996).
The CSTB gene is ubiquitously expressed with a transcript of approximately
0.8 kb in Northern blot analysis (Pennacchio et al., 1996). CSTB spans over a 2.5 kb
genomic region, contains three small exons with coding sequences of 66 bp, 102 bp
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and 129 bp (Fig. 1) (Pennacchio et al., 1996), and two transcription start sites -97 bp
and -108 bp upstream from the translation initiation site (Lalioti et al., 1997b). The
3’untranslated region (UTR) is approximately 250 bp, and the introns 1422 bp and
326 bp in length (Pennacchio et al., 1996). Altogether ten EPM1-associated mutations
(Fig. 1; Table 2, section 3.3.2) have been identified in the CSTB gene (Pennacchio et
al., 1996; Lalioti et al., 1997a; Lalioti et al., 1997b; Kagitani-Shimono et al., 2002; de
Haan et al., 2004; IV).
Figure 1. CSTB gene structure and EPM1-associated mutations. The CSTB gene contains three exons
shown as white boxes with respective lengths of the coding sequences. The translation start (ATG) and
stop (TGA) sites are indicated with white arrowheads. 5’ and 3’UTRs are shown upstream off exon 1
and downstream from exon 3, respectively. The positions of the two transcription start sites, -108 bp
and -97 bp from the translation initiation site, are indicated with black arrowheads. The positions of the
EPM1-associated mutations are shown with arrows. The major mutation underlying EPM1, the
dodecamer repeat expansion, is located in the putative promoter region -175 bp upstream off the
translation initiation site. The novel mutations identified in study IV are framed. Picture modified from
Lehesjoki (2003).
Molecular testing for EPM1 in the Helsinki University Central Hospital,
Laboratory of Molecular Genetics, is available for the repeat expansion, and the
c.10G>C, c.67-1G>C, c.169-2A>G, c.202C>T and c.218_219delTC mutations
(http://www.hus.fi/). Gene testing for EPM1 is also performed in five other DNA
diagnostic laboratories in Europe (http://www.findis.org/; http://www.eddnal.com/).
3.3.1. The dodecamer repeat expansion mutation
An unstable dodecamer (12 bp) 5’-CCCCGCCCCGCG-3’ repeat expansion (Lalioti et
al., 1997b; Virtaneva et al., 1997), the underlying mutation in the majority of EPM1
chromosomes, is detected worldwide in about 90% and in Finland in about 98% of
disease alleles (Lafrenière et al., 1997; Lalioti et al., 1997b; Virtaneva et al., 1997).
This normally polymorphic minisatellite repeat, located in the putative promoter of
CSTB -175 bp upstream off the translation initiation codon (Fig. 1), occurs in 2 to 3
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copies in normal chromosomes, whereas the repeat copy number in expanded alleles
varies from 30 to 125, which translates to sizes from 360 to 1500 bp (Lalioti et al.,
1997b; Virtaneva et al., 1997; Lalioti et al., 1998).
The diagnostic testing of the expansion mutation has been extremely difficult
due to the minisatellite repeat consisting exclusively of G and C nucleotides. The
detection has been largely based on Southern blot analysis of genomic DNAs digested
with PstI (2.6 kb fragment in normal chromosomes), EcoRI (9 kb) or HindIII (5.6 kb)
restriction enzymes and hybridized with CSTB cDNA to detect enlarged fragments
(Lalioti et al., 1997b; Virtaneva et al., 1997). In addition, several methods for the PCR
amplification of the repeat expansion under special conditions have been generated:
PCR amplification followed by hybridization with the oligonucleotide probe
containing the repeat (Lalioti et al., 1998), fluorescent PCR genotyping using an
automated DNA sequencer (Larson et al., 1999), and PCR with deaminated DNAs as
templates (Weinhaeusel et al., 2003; Horiuchi et al., 2005).
The majority of EPM1 patients are homozygous for the repeat expansion
(Lafrenière et al., 1997; Lalioti et al., 1997b; Virtaneva et al., 1997; Moulard et al.,
2002). The origin of the expansion mutation has been investigated in at least three
independent studies characterizing the EPM1 haplotype using microsatellite markers.
The outcome of these studies has been controversial: suggesting only one, a small
number or several origins for this mutation (Lafrenière et al., 1997; Virtaneva et al.,
1997; Moulard et al., 2002). The definitive solution to this issue could be reached
with haplotyping more stable SNP (single nucleotide polymorphism) markers in large
and multinational patient material.
The so-called “premutation” alleles have been identified in the Venezuelan
CEPH (Centre d’Etude du Polymorphisme Humain) families having Huntington’s
disease, but in whom no signs or symptoms of EPM1 have been reported. In these
families the repeat copy number ranges from normal to 17 (Lalioti et al., 1997b).
The normal range of repeats have been shown to form stable secondary
structures that may facilitate strand slippage, thereby causing the expansion (Pataskar
et al., 2001a; Pataskar et al., 2001b). The disease range repeats have been
demonstrated to form tetraplex structures (Fig. 2), which might affect DNA
replication and repair, and/or have an effect on local chromatin structure (Saha and
Usdin, 2001).
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Figure 2. Two different models of the tetraplex structures formed by the bottom strand of the
dodecamer repeat. Picture from Saha and Usdin (2001).
The meiotic instability of the repeat during transmission has been
demonstrated in the EPM1 family pedigrees (Virtaneva et al., 1997; Lalioti et al.,
1998; Larson et al., 1999). The mutation rate (47%) of the EPM1 expansion alleles is
the highest yet observed for any human minisatellite (Larson et al., 1999). Both
contraction and expansion of the repeats have been recognized, typically by a single
repeat unit (Larson et al., 1999). The instability has been detected in both maternal
and paternal transmissions, being greater in paternal ones (Larson et al., 1999),
similarly to that observed with CAG repeats (Ikeuchi et al., 1996). This high mutation
rate might be mediated by DNA replication errors due to the 100% GC content of
considerable length (Larson et al., 1999).
In Northern analyses of mRNA extracted from lymphoblastoid cells,
dramatically reduced mRNA levels were observed in EPM1 patients with
homozygous repeat expansions. This suggests reduced CSTB gene transcription due to
the expansion in the promoter region (Pennacchio et al., 1996; Bespalova et al.,
1997a; Lafrenière et al., 1997; Lalioti et al., 1997b). Decreased cathepsin inhibitory
activity of the CSTB protein in these cells has been demonstrated as well (Rinne et
al., 2002). On the contrary, Lalioti et al. (1997a) detected normal CSTB expression
levels with RNase protection assays of patient lymphoblastoid and fibroblast cell
lines, while in blood leukocytes CSTB levels were markedly reduced, suggesting a
cell-specific regulation of CSTB gene expression.
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The hypermethylation status of the promoter and surrounding CpG-elements
has been investigated by Southern blot analysis with methylation sensitive HpaII and
MspI restriction enzymes (Lalioti et al., 1997b). In blood leukocytes and
lymphoblastoid cell lines of controls, carriers and patients no obvious differences in
DNA methylation was revealed, thus reduction of CSTB expression is presumably not
associated with methylation differences (Lalioti et al., 1997b). However, the
methylation status of the repeat itself has not yet been determined.
No correlation between the expansion size and the age of onset or clinical
severity has been observed (Lafrenière et al., 1997; Lalioti et al., 1997b; Virtaneva et
al., 1997; Lalioti et al., 1998), suggesting that once the size expands beyond a critical
threshold, sufficiently reducing Cstb gene expression, the pathological consequences
are fully developed. The differences in the disease manifestation even among siblings
is likely to be due to the influence of modifier genes and/or environmental factors
(Lalioti et al., 1998).
3.3.2. Other EPM1-associated mutations
The so-called minor EPM1 mutations together account for a small proportion, less
than 10%, of disease alleles worldwide. In compound heterozygous form with the
repeat expansion occur six published mutations (Table 2): the nonsense c.202C>T
(p.Arg68X) (Pennacchio et al., 1996), missense c.212A>C (p.Gln71Pro) (de Haan et
al., 2004), frameshift c.218_219delTC (p.Leu73fsX3) (Lalioti et al., 1997a), and three
splice site mutations, c.67-1G>C (p.delVal23_Lys56) (Pennacchio et al., 1996),
c.168G>A (Kagitani-Shimono et al., 2002) and c.169-2A>G (Lalioti et al., 1997a). In
addition, one EPM1 patient has the missense c.10G>C (p.Gly4Arg) mutation, the only
minor mutation identified in homozygous form (Lalioti et al., 1997a).
The splice site c.67-1G>C mutation, detected in several mostly caucasian
EPM1 patients (Pennacchio et al., 1996; Bespalova et al., 1997b; Lafrenière et al.,
1997; Lalioti et al., 1997a), results in skipping of exon 2 with consequent in-frame
deletion of 34 amino acids (p.delVal23_Lys56) (Bespalova et al., 1997b). This
mutation is the most common of the minor mutations as it has been detected in several
disease chromosomes, whereas the other minor mutations have each been described in
only one or a few chromosomes (Lehesjoki and Koskiniemi, 1999). The exon-intron
boundary c.168G>A mutation, identified in a Japanese patient, causes no amino acid
change, but affects a conserved splice site sequence predicting severe splicing defects
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that are, however, unconfirmed (Kagitani-Shimono et al., 2002). The splice site c.169-
2A>G mutation, found in a French patient, probably results in abnormal splicing, but
this has not been verified (Lalioti et al., 1997a).
Table 2. EPM1-associated mutations in the CSTB gene.
MUTATION CONSEQUENCES POPULATION REFERENCE
Dodecamer repeat
expansion
Reduced mRNA
transcription
Several
populations
(Lafrenière et al., 1997; Lalioti et al., 1997b;
Virtaneva et al., 1997)
c.10G>C p.Gly4Arg Moroccan (Lalioti et al., 1997a)
c.67-1G>C p.delVal23_Lys56 Several
populations
(Pennacchio et al., 1996; Bespalova et al., 1997b;
Lafrenière et al., 1997; Lalioti et al., 1997a)
c.149G>A p.Gly50Glu Finnish IV
c.168G>A Aberrant splicing? Japanese (Kagitani-Shimono et al., 2002)
c.168+1_18del p.delVal23_Lys56
p.Val57GlufsX28
Italian IV
c.169-2A>G Aberrant splicing? French (Lalioti et al., 1997a)
c.202C>T p.Arg68X Finnish
Swedish
Dutch
(Pennacchio et al., 1996; Lafrenière et al., 1997;
de Haan et al., 2004)
c.212A>C p.Gln71Pro Dutch (de Haan et al., 2004)
c.218_219delTC p.Leu73fsX3 French
American
(Bespalova et al., 1997a; Lafrenière et al., 1997;
Lalioti et al., 1997a)
The missense c.10G>C mutation identified in a Moroccan patient (Lalioti et
al., 1997a) results in the substitution of a highly conserved glycine at amino acid
position four (p.Gly4Arg). On the basis of the known crystal structure of CSTB with
papain (Fig. 3, section 4.1), the glycine residue is part of the papain-binding pocket
(Stubbs et al., 1990). The substitution of this glycine by an arginine, with a long and
charged side chain, causes major steric hindrance that is likely to strongly affect the
papain binding of CSTB (Lalioti et al., 1997a). The other published missense
mutation c.212A>C, found in a Dutch patient, results in substitution of a glutamine at
position 71 by a proline (p.Gln71Pro) (de Haan et al., 2004). This mutation site is
located proximal to the second hairpin loop that contributes indirectly to protease
binding (Stubbs et al., 1990; Pol and Björk, 1999), and the mutation is likely to affect
the structure of the fourth beta strand within the second hairpin loop by two residues,
most likely resulting in altered binding affinities.
The nonsense c.202C>T mutation causing an early termination codon and
predicting a truncated p.Arg68X CSTB protein has been identified in Finnish,
Swedish and Dutch patients (Pennacchio et al., 1996; Lafrenière et al., 1997; de Haan
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et al., 2004). The c.218_219delTC mutation causes the deletion of TC in a short
dinucleotide repeat AATCTCTCCC, deleting amino acid Leu73 and creating a
frameshift with two out-of-frame amino acids (proline-serine) before an early stop
codon (p.Leu73fsX3). A truncated protein only 74 amino acids in length, 24 amino
acid shorter than the normal 98 amino acid CSTB protein, is predicted to be produced
(Lalioti et al., 1997a). This mutation has been detected in French and American
patients (Bespalova et al., 1997a; Lafrenière et al., 1997; Lalioti et al., 1997a).
3.3.3. EPM1B, a new locus for Unverricht-Lundborg disease
A systematic study of inherited epilepsies performed in Israel identified mutations in
the CSTB gene in an inbred Arab family (Mazarib et al., 2001), but in another Arab
family living in a nearby town and suffering from similar symptoms mutations were,
unexpectedly, not detected (Berkovic et al., 2005). This family contained eight
affected individuals with progressive myoclonus and ataxia, seven of whom also had
tonic-clonic epileptic seizures. Magnetic resonance imaging (MRI), muscle and skin
biopsies were unremarkable. The disease phenotype was typical of Unverricht-
Lundborg disease, but the mean age of onset was earlier than in EPM1 (7.3 years
versus 11 years for EPM1) (Berkovic et al., 2005). With a genome-wide screen a new
locus for EPM1, named EPM1B, was mapped to chromosome 12 (Berkovic et al.,
2005). This 15-megabase region on 12p11-q13 with a maximum LOD (logarithm of
odds) score of 6.32 contains 47 known genes and numerous predicted genes, and does
not contain any known PME genes or genes known to be related to CSTB (Berkovic et
al., 2005). Identification of this new EPM1B gene may contribute to understanding
the molecular pathogenesis of ULD.
4. Cystatins
Cystatins are inhibitors of papain family cysteine proteases, cathepsins, which they
bind tightly and reversibly (Abrahamson et al., 1986; Brömme et al., 1991; Machleidt
et al., 1991; Lenarcic et al., 1996). Cystatins are thought to participate in the
protection against unwanted proteolysis, through controlling the activities of
endogenous lysosomal proteases by rapidly trapping these enzymes in tight
complexes (Barrett et al., 1986b). They also protect against proteases released from
metastasizing cancer cells (Sloane, 1990) and harmful effects of free cysteine
proteases released from invading microorganisms (North et al., 1990; Stoka et al.,
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1995). Chicken egg white cystatin is the prototype of the group (Fossum and
Whitaker, 1968). All cystatins contain a conserved N-terminal Gly amino acid residue
and a conserved polypeptide sequence of Gln-Val-Val-Ala-Gly (QVVAG) (Barrett et
al., 1986b; Barrett, 1987). Cystatins are divided into three groups on the basis of
functional and structural similarities (Barrett et al., 1986a; Rawlings and Barrett,
1990; http://merops.sanger.ac.uk/). Type 1 cystatins consist of intracellular cystatins
A and B (CSTA and CSTB) that are small molecular weight, 98 amino acid, 12 kDa
proteins with no disulfide bonds or carbohydrate side chains. Cystatins C (CSTC), D,
E/M, F, S, SA and SN, the type 2 cystatins, are larger in size (approximately 120
residues, 13 kDa), and contain two disulfide bridges and a signal sequence for
extracellular targeting, but still no carbohydrate side chains. The plasma L- and H-
kininogens, type 3 cystatins, are large (50-114 kDa) multifunctional glycoproteins.
They consist of three divergent copies of type 2 like cystatin sequences, and contain
several disulfide bonds.
CSTA inhibits lysosomal cathepsins B, C, H, L and S, as well as cysteine
proteases from parasites e.g. cruzipain, and some plant proteases e.g. papain and
actinidin (Green et al., 1984; Abrahamson et al., 1986; Pol et al., 1995; Stoka et al.,
1995; Leonardi et al., 1996). The three-dimensional structure of CSTA has been
determined and similarity between free CSTA and CSTB in complex with papain is
considerable, but there is also conformational differencies in their protease binding
regions (Martin et al., 1995). The expression pattern of CSTA is quite restricted, with
high levels in skin, where it takes part in the epidermal barrier formation (Nemes and
Steinert, 1999), and in some blood cells. CSTA is not associated with any disease
phenotype and is little studied.
The mature CSTC protein is composed of 120 amino acid residues, but is
synthesized as a preprotein with a 26 amino acid signal peptide (Barrett et al., 1984;
Abrahamson et al., 1987; Merz et al., 1997). CSTC is a strong inhibitor of cathepsins
B, H, L and S, and is distributed in most human tissues and fluids (Löfberg and
Grubb, 1979; Grubb et al., 1983; Abrahamson et al., 1986; Barrett, 1986) with
particular abundance in the cerebrospinal fluid (Abrahamson et al., 1986). The CSTC
protein has amyloidogenic properties and colocalizes with beta-amyloid in
degenerated neurons in Alzheimer’s disease, suggesting a role in neuronal
degeneration (Deng et al., 2001; Levy et al., 2001). Defects in the CSTC protein cause
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hereditary cerebral hemorrhage with amyloidosis (HCHWA), which is characterized
by amyloid fibril deposits in the cerebral arteries leading to massive brain hemorrhage
and death in young adults (Ghiso et al., 1986; Palsdottir et al., 1988). In Cstc-deficient
mice no gross pathological abnormalities have been detected (Huh et al., 1999; Olsson
et al., 2004).
4. 1. The cystatin B (CSTB) protein
CSTB, also known as Neutral Cysteine Protease Inhibitor (NCPI) and stefin B, was
first found and characterized in lymphatic tissue (Rinne, 1981; Järvinen and Rinne,
1982) and liver (Ritonja et al., 1985). CSTB has isoelectric variants (Rinne, 1981;
Järvinen and Rinne, 1982) and often forms dimers, which are stabilized by
noncovalent forces. It is found mainly intracellularly and is widely distributed among
different cell types and tissues. CSTB binds in vitro tightly and reversibly to
cathepsins H, L and S, and less to cathepsin B (Green et al., 1984; Abrahamson et al.,
1986; Barrett, 1986; Brömme et al., 1991; Machleidt et al., 1991; Lenarcic et al.,
1996). In addition, CSTB has been shown to inhibit cathepsin K activity in osteoclasts
(Laitala-Leinonen et al., 2005).
In EPM1 patient lymphoblastoid cell lines biochemical studies have revealed
that the CSTB inhibitory activity is significantly reduced (or absent) and correlates
with increased cathepsins B, L and S activity (Rinne et al., 2002), while cathepsin H
activity is not significantly altered (Rinne et al., 2002). These findings demonstrate
that the activity of these cathepsins is regulated in vivo by CSTB. In the rat kindling
model of epilepsy, markedly increased Cstb mRNA and protein expression was
detected 6 and 24 hours after kindling-induced epileptic seizures in forebrain neurons.
This implies that upregulation of Cstb following seizures may counteract apoptosis by
binding cathepsins, supporting the hypothesis of a neuroprotective role for CSTB
(D'Amato et al., 2000).
Cstb expression has been investigated in two large-scale expression analyses
of mouse orthologues of the entire transcriptome of human chromosome 21 with
emphasis on identifying candidate genes for the pathogenesis of Down syndrome
(Gitton et al., 2002; Reymond et al., 2002). Reymond et al. (2002) presented an
expression atlas of 161 genes using RNA in situ hybridization on whole mount
embryos at embryonic day 9.5 (E9.5) and E10.5 and in tissue sections at E14.5, and
by RT-PCR in adult tissues. Gitton et al. (2002) studied expression of 158 genes using
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RNA in situ hybridization at E9.5 embryos and in postnatal day 2 (P2) brain and in
silico computer mining of expressed sequence tags. Cstb was expressed in several
embryonal tissues (Reymond et al., 2002) or alternatively in the entire embryos
(Gitton et al., 2002). In adult mouse, Cstb was expressed in almost all tissues
examined (Reymond et al., 2002). In adult rat brain Cstb was detected to be
differentially expressed in several brain areas with RNA in situ hybridization and
immunohistochemistry. Cstb expression was highest in the hippocampal formation
and reticular thalamic nucleus (D'Amato et al., 2000).
On the cellular level CSTB protein has been thought to localize to several
intracellular compartments. At first CSTB was considered to be a soluble cytoplasmic
protein (Stubbs et al., 1990). Later, using immunofluorescence analysis, CSTB was
shown to be concentrated at the membranes of many vesicles in hepatoma cells
(Calkins et al., 1998) and also to localize in the nucleus (D'Amato et al., 2000). It was
also detected in cytoplasmic granular structures, representing either the Golgi
complex or lysosomes, in a variety of cell lines (Riccio et al., 2001).
Figure 3. Ribbon model of a complex of CSTB (N-terminal region and the α-helix, shown with yellow
color, and the β-sheets with red and orange colors) with papain (shown with green and blue colors).
Modified from Stubbs et al. (1990).
The 3D-structure of the recombinant human CSTB-papain complex has been
determined (Fig. 3) (Stubbs et al., 1990). CSTB consist of a five-stranded β-sheet
wrapped around a five-turn α-helix and a C-terminal strand running along the convex
side of the sheet. CSTB interacts with papain through a tripartite wedge formed by
conserved residues at the N-terminal end, the first hairpin loop containing the highly
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conserved QVVAG sequence and the second hairpin loop. The C-terminus provides
an additional interaction region. The interactions are mostly hydrophobic contacts
(Stubbs et al., 1990).
CSTB may counteract inappropriate proteolysis by inhibiting cathepsins that
leak out into the cytoplasm from the lysosomes, but may also be involved in other
cellular prosesses either through cathepsin interactions or other mechanisms. For
example, growing evidence for nuclear localization has led to the idea that CSTB
might be involved in prosesses other than proteolysis. Therefore, the full
physiological function of CSTB is still unknown.
4.1.1. Mammalian model for EPM1: Cstb-deficient mouse
A mammalian model for the human EPM1 disease has been produced by targeted
disruption of the mouse Cstb gene (Pennacchio et al., 1998). The mouse Cstb gene
encodes a 98 amino acid polypeptide identical in length to the human and rat proteins,
with 79% and 86% amino acid similarity, respectively (Pennacchio and Myers, 1996).
Cstb-deficient mice develop a phenotype that resembles the human disease, with
progressive ataxia and myoclonic seizures. However, no tonic-clonic seizures or
photosensitivity, typical in human EPM1 patients, have been observed (Pennacchio et
al., 1998). Myoclonic seizures occured only during sleep and developed by 1 month
of age. While signs of ataxia were detected at 6 months of age (Pennacchio et al.,
1998). Analysis of mice revealed apoptotic death of cerebellar granule cells
(Pennacchio et al., 1998). Less marked neuronal apoptosis was detected in the
hippocampal formation and entorhinal cortex in 3- to 4-month-old mice (Shannon et
al., 2002). In older mice, gliosis was present in the hippocampal formation, entorhinal
cortex, neocortex and striatum. Widespread gliosis was also present in the white
matter, which may be a secondary phenomenon. The superficial neurons of the
prosubiculum in the cerebral cortex displayed prominent cellular atrophy (Shannon et
al., 2002). Myoclonic seizures were only visible in an isogenic 129Sv background,
while ataxia and abnormal brain histology were present in both mixed and isogenic
backgrounds (Pennacchio et al., 1998; Shannon et al., 2002).
Transcriptional profiling of Cstb-deficient mice brains have shown increased
expression of seven genes: cathepsin S (Ctss), C1q B-chain of complement (C1qB),
β2-microglobulin, glial fibrillary acidic protein (Gfap), apolipoprotein D, fibronectin
1 and metallothionein II, which are involved in proteolysis, apoptosis and glial
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activation (Lieuallen et al., 2001). Ctss was the known target of Cstb, while the other
transcripts found encode proteins that are known to be involved in responding to
neuronal damage. The increased levels of Ctss were a consistent alteration, while
cathepsins B, H and L levels were found to vary inconsistently (Lieuallen et al., 2001)
Therefore Ctss was suggested to be involved in the apoptosis seen in EPM1.
However, no improvement of EPM1 phenotype was seen in a mouse model doubly
deficient for Cstb and Ctss (see below, section 5.2) (Houseweart et al., 2003a).
A hypothesis of whether cathepsins in the absence of the proapoptotic Bcl-2
family member Bid promote apoptosis in vivo has been tested in mice doubly
deficient for Cstb and Bid (Houseweart et al., 2003b). In vitro studies had suggested
that cathepsins can induce apoptosis by cleaving Bid (Stoka et al., 2001). In these
mice the phenotypes of apoptosis, ataxia and seizure were not decreased, and
cathepsins still promote apoptosis, indicating that apoptosis is mediated via a different
pathway or some other molecule can substitute the function of Bid (Houseweart et al.,
2003b).
5. Cathepsins
Lysosomal proteases, cathepsins, are involved in intracellular and extracellular
protein degradation as well as in a range of cellular processes such as major
histocompatibility complex antigen presentation and bone remodelling (Riese and
Chapman, 2000). There are two aspartic (cathepsins D and E) and 13 known cysteine
(cathepsins B, C, F, H, K, L, N, O, S, T, V, X and W) lysosomal proteases.
Cathepsins B, D and L are the most abundant. From now onwards only cathepsins
belonging to cysteine proteases are discussed. The cathepsins have acidic pH-optima,
with the exception of CTSS which retains its proteolytic activity also at physiological
pH (Kirschke et al., 1989; Kirschke and Wiederanders, 1994). Cathepsins B, C, F, H,
L, O and X are ubiquitously expressed in mammalian tissues, while CTSK is mainly
found in osteoclasts, CTSS mainly in spleen, lymphocytes, monocytes and peripheral
antigen-presenting cells, CTST in kidney, spleen and liver, CTSV in thymus and
testis, and CTSW in T lymphocytes (Brömme et al., 1996; Linnevers et al., 1997;
Santamaria et al., 1998; Turk et al., 2000).
Defects in CTSK  cause pycnodysostosis, an osteochondrodysplasia
characterized by osteopetrosis, short stature due to premature closure of long bone
32 Kirsi Alakurtti
growth and other severe bone abnormalities (Andren et al., 1962; Maroteaux and
Lamy, 1962), suggesting CTSK to be a major protease in bone resorption (Gelb et al.,
1996). Interestingly, CSTB has been recently considered to have regulatory functions
in osteoclasts, where it could inhibit bone resorption by down-regulating intracellular
CTSK activity (Laitala-Leinonen et al., 2005).
5. 1. Cathepsin-deficient mice
The molecular roles of cathepsins have been studied through generating gene targeted
mice, e.g. Ctsb-, Ctsk-, Ctsl- and Ctss-deficient mice. The Ctsb-deficient mice have no
spontaneous pathological phenotype, suggesting redundancy of Ctsb function
(Deussing et al., 1998; Halangk et al., 2000). The Ctsk-deficient mice displayed an
osteopetrotic phenotype with excessive trabeculation of the bone-marrow space,
further confirming the importance of Ctsk in bone resorption (Saftig et al., 1998;
Saftig et al., 2000; Kiviranta et al., 2005). The Ctsl-deficient mice developed periodic
hair loss, and epidermal hyperplasia, acanthosis and hyperkeratosis (Roth et al.,
2000), and significant ventricular and atrial enlargements that were associated with a
comparatively small increase in relative heart weight (Stypmann et al., 2002). In
addition, both heterozygote and homozygote Ctsl-deficient mice had significantly
decreased trabecular, but not cortical, bone volume (Potts et al., 2004). These
phenotypes indicate the importance of Ctsl for instance in epidermal homeostasis,
regulation of hair follicle morphogenesis and cycling, cardiac morphology and
function, and controlling bone turnover. Further, a missense mutation in Ctsl was
identified as the molecular basis (Roth et al., 2000) of the previously-known furless
mouse (Green, 1954). The Ctss-deficient mice displayed profound inhibition of
invariant chain (Ii) degradation resulting in an impaired MHC class II peptide loading
(Nakagawa et al., 1999; Shi et al., 1999) and defective microvessel development
during wound repair (Shi et al., 2003). These findings suggest that Ctss is essential for
effective Ii proteolysis and has a role in extracellular matrix degradation during
microvessel formation.
The functional redundancy and function of cathepsins was investigated by
combining Ctsb- and Ctsl-deficient mouse strains. A double deficiency of Ctsb and
Ctsl was lethal during the second to fourth week of life, and associated with a degree
of brain atrophy not previously seen in mice (Felbor et al., 2002). A massive amount
of apoptosis of certain neurons was detected in the cerebral cortex, and in the Purkinje
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and granular cell layers of the cerebellum. In addition to neurodegeneration,
pronounced reactive astrocytosis, accumulation of ultrastructurally and biochemically
unique lysosomal bodies in large cortical neurons, and axonal enlargements were
detected. These findings indicate the essential role of Ctsb  and Ctsl  in the
maintenance of the central nervous system (Felbor et al., 2002).
5. 2. Mice double deficient for Cstb and cathepsins B, L or S
To find out the contribution of cathepsins to the EPM1 phenotype mice doubly
deficient for Cstb and either Ctsb, Ctsl or Ctss were created (Houseweart et al.,
2003a). The removal of Ctsl and Ctss from Cstb-deficient mice did not improve any
aspects of the EPM1 phenotype, whereas the removal of Ctsb resulted in 36-89%
reduction in the amount of cerebellar granule cell apoptosis depending on the mouse
age, as well as reduced the incidence of an incompletely penetrant eye phenotype. The
ataxia and seizure phenotypes were not diminished. These results indicated that in the
absence of an endogenous inhibitor, Ctsb can initiate or propagate apoptosis. Since
the ataxia and seizure phenotypes were not dimished, another molecule, in addition to
Ctsb, is probably involved in the pathogenesis of EPM1 or can partially compensate
for its function. In addition, as the removal of any of these cathepsins did not totally
improve the EPM1 phenotype, Cstb may have other functions beside protease
inhibition (Houseweart et al., 2003a).
6. Features of eukaryotic promoters
Most biological processes are regulated at the level of gene transcription.
Transcription in eukaryotic cells is conducted by three different RNA polymerases.
RNA polymerase II (RNAP II) transcribes promoters of mRNA encoding genes.
These promoters contain three types of DNA elements. Basal promoter elements are
located near the transcription start site and bind the general transcription machinery
proteins. Sequence-specific transcription factors bind to proximal promoter elements
that lie upstream of the gene and to distal enhancer elements that can be located
several kilobases away from the start site.
General transcription factors (GTFs) include TFIIA, -B, -D, -E, -F and -H that
are needed for RNAP II mediated basal transcription. TFIID is composed of TATA-
binding protein (TBP) and TBP-associated factors (TAFs) (Orphanides et al., 1996;
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Woychik and Hampsey, 2002). TBP binds to a TATA box, an element located -31 to -
26 bp upstream of the transcription start site. The TFIIB recognition element (BRE) is
located -37 to -32 bp, initiator (Inr) -2 to +4 bp, and downstream promoter element
(DPE) +28 to +32 bp from the start site. Different TAFs interact with DPE and Inr.
Most core promoters contain a TATA element, and the minority of them that do not
are called TATA-less promoters, and usually contain a compensatory DPE motif. The
TATA box can function in the absence of BRE, Inr and DPE motifs, but DPE requires
the presence of Inr (Butler and Kadonaga, 2001; Smale and Kadonaga, 2003).
The general transcription machinery containing RNAP II and GTFs is
sufficient to promote basal gene transcription in vitro, whereas additional factors are
required for the response to activators. The mediator complex is unable to bind
specific DNA sequences, but transmits regulatory information from gene specific
transcription factors to the core transcription machinery and is required for regulated
transcription initiation (Flanagan et al., 1991). Insulator DNAs are needed to prevent
an enhancer associated with one gene from inappropriately regulating neighboring
genes (Burgess-Beusse et al., 2002). Sequence-specific factors are required to achieve
efficient transcription and specific regulation of gene expression within a specific
tissue or cell type (Orphanides et al., 1996; Woychik and Hampsey, 2002). There may
be as many as 3000 transcription factors in humans (Lander et al., 2001a),
highlighting the complexity of transcriptional regulation. In the following paragraphs
some of the essential sequence-specific transcription factor families are introduced as
examples.
AP1 (activating protein 1) consists of dimeric transcription factors composed
of Jun, Fos or ATF (activating transcription factor) subunits that bind to common
DNA sites, the AP1 sites, also known as the TPA (12-O-tetradecanoylphorbol 13-
acetate)-responsive elements (TRE). The common feature among AP1 family
members is the evolutionarily conserved bZIP (basic region leucine zipper) domain.
The consensus sequence of AP1 sites is 5’-TGAG/CTCA-3’ (Vogt and Bos, 1990;
Angel and Karin, 1991; Karin et al., 1997). These proteins are differentially expressed
and regulated, which results in different cell types having a complex mixture of AP1
dimers with different functions (Wagner, 2001).
The GC-boxes or CpG islands containing the sequence 5’-GGGGCGGGG-3’
are important DNA regulatory elements widely distributed in promoters and
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enhancers of housekeeping and tissue-specific genes. The human genome contains
approximately 29000 of these CpG islands, which can also be modified by
methylation. Sp1 (specificity protein 1) was the first identified transcription factor that
binds to the GC-box regulatory elements (Dynan and Tjian, 1983a; Dynan and Tjian,
1983b). However, nowadays there are at least eight known transcription factors which
share common structural features and DNA binding specificities with Sp1 (Zhao and
Meng, 2005). All of these members contain a conserved DNA-binding domain
consisting of three zinc fingers (Philipsen and Suske, 1999; Suske, 1999). Sp1 and
Sp3 are both ubiquitously expressed, and while Sp3 also has the capacity to repress
transcription, they compete for the same binding sites and it has been assumed that
their relative abundance allows regulation of gene activities of different cell types
(Suske, 1999). Sp4, a tissue restricted activator, is predominantly expressed in the
CNS, but is also detectable in epithelial tissues, testis and developing teeth (Hagen et
al., 1992). Proteins Sp5 through Sp9 are shorter in their amino acid lengths and are
expressed in tissue-restricted manners. Sp1-like transcription factor family members
have diverse functions during embryonic development, though the specific function of
each member of the family is difficult to clarify due to overlapping expression and
similar DNA binding properties (Zhao and Meng, 2005).
The basic-helix-loop-helix (bHLH) transcriptional regulatory proteins are key
players in numerous developmental processes. The family consists of seven classes of
bHLH proteins that bind to a consensus sequence 5’-CANNTG-3’, called the E-box.
The basic region acts as sequence-specific DNA-binding domain, which recognizes
the E-box binding site and has additional preference for internal and flanking
sequences (Blackwell and Weintraub, 1990). bHLH proteins form dimers through the
interaction of their HLH domains and each half of the dimer recognizes one half of
the E-box (Murre et al., 1989). Specific subfamilies of bHLH proteins act in the
differentiation of various cell types. Myogenic regulatory factors (MRFs), bHLH class
II proteins, are critical for the determination and terminal differentiation of skeletal
muscle cells. MRFs consist of MyoD, Myf5, myogenin and Mrf4 (Lassar et al., 1986;
Molkentin and Olson, 1996). The NeuroD subfamily, also bHLH class II proteins, is
largely restricted to neural and neuroendocrine cells, and regulates neuronal
specification and differentiation (Bertrand et al., 2002). This subfamily contains
NeuroD, Mash1, Neurogenin1-3 (Ngn1-3) and Math1/3 (Anderson et al., 1997; Lee,
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1997; Schuurmans and Guillemot, 2002). The E-protein subfamily, bHLH class I
proteins, which include E12, E47, HEB and E2-2, are expressed in many tissues and
are capable of forming either homo- or heterodimers. With few exceptions, class II
proteins are incapable of forming homodimers and preferentially heterodimerize with
an E-protein (Murre et al., 1989).
The nuclear steroid receptors form a large group of transcription factors with
high homology in the DNA-binding domain and lower homology in the
carboxyterminal ligand-binding domain (Evans, 1988; Lubahn et al., 1988). The
androgen receptor (AR), glucocorticoid receptor (GR), progesterone receptor (PR)
and mineralocorticoid receptor (MR) form a subgroup within the nuclear receptor
family (Glass, 1994). These receptors bind to the glucocorticoid response element
(GRE), also called progesterone response element (PRE) or androgen response
element (ARE), whose consensus sequence is 5’-AGAACAnnnTGTTCT-3’ (Nordeen
et al., 1990; Roche et al., 1992; Lieberman et al., 1993; Lombes et al., 1993).
The nuclear factor (NF1) family, also known as CAAT box transcription
factors (CTFs), are composed of four members NFI-A, -B, -C and -X. NFI proteins
can both activate and repress expression on consensus binding sites 5’-TTGGC(N5)
GCCAA-3’, which have been characterized from genes expressed in almost every
organ system and tissue (Gronostajski, 2000).
7. Disease associated repeat expansion mutations
Repeat expansion is a unique form of mutation that is linked to more than 40
neurological, neurodegenerative and neuromuscular disorders. The first identified
pathogenic repeat mutations were in fragile X syndrome (FRAXA) (Kremer et al.,
1991; Verkerk et al., 1991), and in spinal and bulbar muscular atrophy (SBMA) (La
Spada et al., 1991). Repeat expansion disorders not only include trinucleotide repeats,
but also tetranucleotide (myotonic dystrophy type 2 [DM2]), pentanucleotide
(spinocerebellar ataxia type 10 [SCA10]), minisatellite (EPM1, Creutzfeldt-Jakob
disease [CJD] and diabetes) and megasatellite repeats (facioscapulohumeral muscular
dystrophy type 1A [FSHMD1A]) (Wijmenga et al., 1992; Owerbach and Gabbay,
1993; Lalioti et al., 1997b; Matsuura et al., 2000; Liquori et al., 2001).
Beyond expansion of a repeat, the genetics of these diseases seem to have little
in common. Genes carrying expanded repeats can be situated on the X chromosome
Molecular biology of progressive myoclonus epilepsy of Unverrich-Lundborg type (EPM1) 37
or autosomes, and the pattern of inheritance can be dominant, recessive or
multifactorial (Table 3). Target genes have no evident functional similarities and
repeats are located in various parts of genes resulting in either loss or gain of function.
Repeat expansions in non-coding regions cause disorders resulting either from a loss-
of-function through to inhibiting gene expression (Pandolfo, 1998; Jin and Warren,
2000) or from an RNA-mediated gain-of-function mechanism, in which the expanded
RNA transcripts form imperfect double-stranded structures that accumulate and
disrupt RNA-processing functions (Ranum and Cooper, 2006). Repeat expansions in
coding regions can lead to change of function of the mutant protein or to a protein
gain-of-function through poly-amino acid stretches, which may lead to self-
aggregation and aggregation with other proteins (Orr and Zoghbi, 2001). In the
following paragraphs specific features of some of these diseases associated with
repeat expansion mutations in non-coding, coding and other chromosomal locations
are highlighted (Table 3).
Table 3. Diseases associated with repeat expansion mutations.
DISEASE INHERITANCE GENE LOCALIZATION REPEAT SEQUENCE NORMAL MUTATION
NON-CODING
DM11 AD DMPK 3’UTR CTG 5-38 50-2000
DM22 AD ZNF9 intron CCTG 10-26 75-11000
EPM13 AR CSTB promoter CCCCGCCCCGCG 2-3 30-125
FRDA4 AR FXN intron GAA 6-36 90-1700
FRAXA
FXTAS/POF5
XD FMR1 5’UTR CGG 6-60 200-2000
55-200
FRAXE6 XR FMR2 5’UTR CCG 4-39 200-900
SCA107 AD ATXN10 intron ATTCT 10-22 500-4500
SCA128 AD PPP2R2B promoter and 5’UTR CAG 7-45 55-78
CODING
CJD9 AD PRNP exon 24 bp 5 6-13
DRPLA10 AD ATN1 exon CAG 7-34 49-88
HD11 AD HD exon CAG 11-34 40-121
SBMA12 XR AR exon CAG 9-36 38-62
BOTH CODING AND NON-CODING
SCA813 AD ATXN8OS
ATXN8
3’UTR
exon
CTG
CAG
16-34 74-1300
HDL214 AD JPH3 exon and 3’UTR CTG 6-28 43-78
OTHER CHROMOSOMAL LOCATIONS
Class I Class III
DM15 MF INS VNTR 14-15 bp 26-63 141-209
The pattern of inheritance can be X-linked (X), or autosomal (A) and dominant (D) or recessive (R) as well as
multifactorial (MF). 1(Brook et al., 1992); 2(Liquori et al., 2001); 3(Lalioti et al., 1997b); 4(Campuzano et al.,
1996); 5(Kremer et al., 1991; Verkerk et al., 1991; Oostra and Willemsen, 2003); 6(Knight et al., 1993; Gecz et al.,
1996; Gu et al., 1996); 7(Matsuura et al., 2000); 8(Holmes et al., 1999); 9(Owen et al., 1989; Owen et al., 1990);
10(Koide et al., 1994); 11(Huntington's Disease Collaborative Research Group, 1993); 12(La Spada et al., 1991);
13(Koob et al., 1999; Moseley et al., 2006); 14(Holmes et al., 2001b); 15(Owerbach and Gabbay, 1993).
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Myotonic dystrophy type 1 (DM1) is caused by a CTG expansion, located in
the 3’UTR of the dystrophia myotonica-protein kinase (DMPK) gene (Brook et al.,
1992). DMPK is a serine/threonine protein kinase detected only in muscles (Brook et
al., 1992). Myotonic dystrophy type 2 (DM2) is caused by a CCTG expansion in
intron 1 of the zinc finger 9 (ZNF9) gene (Liquori et al., 2001). ZNF9 is a nucleic acid
binding protein that is highly expressed in skeletal muscle and has been suggested to
modulate the activity of the beta-myosin heavy chain (Flink and Morkin, 1995). Both
diseases are mediated by an RNA-mediated gain-of-function mechanism (Liquori et
al., 2001; Ranum and Day, 2004a).
Most Friedreich ataxia (FRDA) patients have homozygous GAA repeat
expansions within the first intron of the frataxin (FXN) gene, which results in loss-of-
function (Campuzano et al., 1996; Campuzano et al., 1997). FXN is involved in
mitochondrial iron metabolism (Rotig et al., 1997). The loss of FXN leads to
accumulation of mitochondrial iron, increased susceptibility to oxidative stress and
reduction in oxidative phosphorylation (Wilson, 2003).
Fragile X mental retardation (FRAXA) is caused by a CGG expansion of
greater than 200 repeats in the 5’UTR of the fragile X mental retardation 1 (FMR1)
gene through a loss-of-function mechanism (Kremer et al., 1991), whereas smaller
“premutation” expansions (55-200 repeats) can cause fragile X tremor ataxia
syndrome (FXTAS) and possibly premature ovarian failure (POF) through an RNA
gain-of-function mechanism (Oostra and Willemsen, 2003; Hagerman and Hagerman,
2004). The FMR1 protein is proposed to act as a regulator of mRNA transport and/or
translation (Corbin et al., 1997). FRAXE patients have expansion of a CCG repeat in
the 5’UTR of the fragile X mental retardation 2 (FMR2) gene, which leads to
hypermethylation of the CpG island and transcriptional silencing (Knight et al., 1993;
Gecz et al., 1996; Gu et al., 1996). FRM2 is a potential transcription factor (Gecz et
al., 1997).
Spinocerebellar ataxia type 8 (SCA8), a dominantly inherited disease of
reduced penetrance, is caused by a CTG expansion located in the 3’UTR of the non-
coding ataxin 8 opposite strand (ATXN8OS) gene (Koob et al., 1999) that overlaps
with the 5’UTR of the Kelch-like 1 (KLHL1) gene in the opposite direction.
ATXN8OS might regulate KLHL1, which encodes an actin-binding protein, through an
antisense mechanism (Nemes et al., 2000). Expansion in ATXN8OS is also proposed
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to cause SCA8 by an RNA gain-of-function mechanism (Ranum and Day, 2004b). On
the opposite strand the CAG expansion is also located in the newly discovered ataxin
8 (ATXN8) gene. The expansion in ATXN8 produces a protein that contains only
glutamine residues, and is suggested to cause the disease by a protein gain-of-function
mechanism (Moseley et al., 2006). SCA10 is caused by a large expansion of an
intronic ATTCT repeat in the spinocerebellar ataxia 10 (ATXN10) gene (Matsuura et
al., 2000) and is probably mediated by an RNA-mediated gain-of-function mechanism
(Lin and Ashizawa, 2005). The CAG repeat expansion in SCA12 is located either in
the promoter region or 5’UTR of the protein phosphatase 2 (PPP2R2B) gene,
depending on different transcript transcriptional start sites (Brook et al., 1992; Holmes
et al., 1999). The expansion mutation effect is through increasing the gene expression
and an RNA gain-of-function mechanism (Holmes et al., 1999; Holmes et al., 2001a;
Holmes et al., 2003).
Creutzfeldt-Jakob disease (CJD) is caused by a 24 bp minisatellite repeat
expansion in the prion protein (PRNP) gene causing octapeptide repeats in the prion
protein (PrP) (Owen et al., 1989; Owen et al., 1990). The cellular isoform PrPC is
converted to an abnormal conformed scrapie isoform PrPSc, which is an infectious
agent.
Dentatorubral-pallidoluysian atrophy (DRPLA) (see earlier, section 2) is
caused by a CAG repeat in the coding region of the adenine nucleotide translocator
atrophin 1 (ATN1) gene (Koide et al., 1994), forming polyglutamine stretches. ATN1
is involved in repression of transcription (Zhang et al., 2002).
Huntington’s disease (HD) is caused by a CAG repeat within the coding
region of the huntingtin (HD) gene, which is translated as a polyglutamine repeat in
the protein product (Huntington's Disease Collaborative Research Group, 1993). The
proposed mechanisms includes altered transcription, protein aggregation, altered
protein interaction or function, proteolytic cleavage of HD or defects in
neurotransmitter signalling (Lee and Kim, 2006). Huntington disease-like 2 (HDL2) is
caused by a CTG expansion, which depending on the splicing is located either in a
variably spliced exon of the junctophilin 3 (JPH3) gene leading to polyalanine or
polyleucine stretches, or in the 3’UTR leading to an RNA-mediated gain-of-function
mechanism (Holmes et al., 2001b). JPH3 is a plasma membrane/endoplasmic
reticulum junction protein (Takeshima et al., 2000).
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Spinal and bulbar muscular atrophy (SBMA) caused by a CAG expansion (La
Spada et al., 1991) in the coding region leads to polyglutamine disease through
accumulation of mutant androgen receptor (AR), a hormone-activated transcription
factor (Chang et al., 1988).
A variable number of tandem repeat (VNTR) regulatory polymorphism,
located in the promoter region of the insulin gene (INS), is associated with
susceptibility to diabetes. The VNTR consists of 14-15 bp oligonucleotides related to
the sequence ACAGGGGTGTGGGG (Owerbach and Gabbay, 1993). The number of
repeats varies and form three classes: class I (26-63 repeats), class II (mean of 80
repeats) and class III (141-209 repeats). The class I homozygous genotype is
associated with elevated risk of developing type 1 diabetes mellitus (DM), while the
class III allele is associated with e.g. type 2 diabetes and larger size at birth (Bennett
and Todd, 1996; Bennett et al., 1996; Dunger et al., 1998).
The premutation associated with e.g. HD and FRAXA refers to an
intermediate number of repeats that on transmission can increase to disease length.
Anticipation, the genetic phenomenon in which disease severity increases and/or age
of onset of disease decreases from one generation to the next as the repeat expansion
becomes longer, is associated with e.g. FRAXA, DM1, SBMA, HD and FRDA.
Molecular biology of progressive myoclonus epilepsy of Unverrich-Lundborg type (EPM1) 41
AIMS OF THE PRESENT STUDY
Prior to this study, the CSTB gene responsible for Unverricht-Lundborg disease had
recently been identified (Pennacchio et al., 1996). With the aim of enhancing our
understanding of the disease pathogenesis of EPM1 this study was undertaken to
analyze the regulation and expression of the CSTB gene, and to initiate the
characterization of the CSTB protein.
The specific aims of this study were to:
• Characterize the CSTB gene.
• Determine the spatial and temporal expression of the Cstb gene.
• Define the subcellular localization of the CSTB protein.
• Study the consequences of EPM1-associated mutations on CSTB gene and
CSTB protein expression.
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MATERIALS AND METHODS
1. Ethical considerations
EPM1 patients and carriers gave informed consent for performing genetic, molecular
or biochemical analyses before the blood or skin samples were collected. The project
has been approved by the Ethical Committee of the Department of Medical Genetics,
University of Helsinki. Mice care and handling were conducted according to the
National Research Council’s guide for the care and use of laboratory animals.
2. EPM1 patients and control individuals
EPM1 patients, carriers and controls were chosen from among individuals included in
the earlier phase of the project. Two novel EPM1 patients were referred to us for
mutation analysis by clinicians. EPM1 patients’ and mutation carriers’ total RNA (I,
IV), genomic DNA (IV) and/or proteins (III, IV) were extracted from blood,
lymphoblastoid cells or fibroblasts as described in I, III and IV. Samples from
unrelated Finnish and Centre d’Etude du Polymorphisme Humain (CEPH)
(http://ccr.coriell.org/nigms/ceph/ceph.html) individuals were used as well.
3. Mouse embryos and tissues
For whole-mount RNA in situ hybridization NMRI mouse embryos at E7 and E8
were collected. Previous and novel cryosections of mouse embryos from various wild-
type mice strains at E14 and E17, and mouse brains at P1, P5, P21 and adult were
used.
4. DNA constructs
The constructs containing different length CSTB promoters, wild-type or mutant
human CSTB and CSTB2 or mouse Cstb and Cstb2 in suitable plasmid vectors
produced and used in the study are summarized in Table 4. The CSTB2 cDNA in
pcDNA3.1(+) vector (Invitrogen) was generated with primers 5’-CAA GAT GAT
GTG CGG GG-3’ and 5’-GCT CTG GTA GAC GGA GGA TG-3’ and mutations
c.10G>C (p.Gly4Arg) and c.149G>A (p.Gly50Glu) were introduced using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene). The 299 bp fragment of
Cstb2 in pBluescript SK(+) vector (Stratagene), used as probe in RNA in situ
hybridization, was generated with primers 5’-tcc acc gcg gtg gcg gcc gcg gCA TGA
ACT GGG GAC ATA G-3’ and 5’-ccc ccc ctc gag gtc gaC TGG AGG AAG ACA
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GAC AGA CAG A-3’ (this thesis), containing NotI or SalI restriction sites
(underlined), respectively.
Table 4. Plasmids constructed.
NAME PLASMID PUBLICATION
CSTB promoter 5873 bp pbluescript SK(-) I
CSTB promoter -670 to -1 bp pGL3-Basic I
CSTB promoter -228 to -1 bp pGL3-Basic I
CSTB promoter -145 to -1 bp pGL3-Basic I
CSTB promoter -670 to -1 bp + 19x 12-mer pGL3-Basic I
CSTB promoter -670 to -514 bp and -411 to -1 bp pGL3-Basic I
CSTB pcDNA3.1(+) III
CSTB p.Gly4Arg pcDNA3.1(+) III
CSTB p.delVal23_Lys56 pcDNA3.1(+) IV
CSTB p.Gly50Glu pcDNA3.1(+) IV
CSTB p.Arg68X pcDNA3.1(+) III
CSTB p.Gln71Pro pcDNA3.1(+) III
CSTB p.Leu73fsX3 pcDNA3.1(+) III
CSTB2 pcDNA3.1(+) this thesis
CSTB2 p.Gly4Arg pcDNA3.1(+) this thesis
CSTB2 p.Gly50Glu pcDNA3.1(+) this thesis
Cstb 544 bp RNA in situ hybridization probe pbluescript SK(+) II
Cstb 173 bp RNA in situ hybridization probe pbluescript SK(+) II
Cstb2 RNA in situ hybridization probe pbluescript SK(+) this thesis
5. Cell lines
Commercially available cell lines COS-1 (African green monkey kidney cells) (I, III,
IV) and BHK-21 (baby hamster kidney cells) (III, IV, this thesis) from the American
Type Culture Collection (ATCC), as well as human primary pectoral muscle
myoblasts (kindly provided by Olli Carpén, University of Helsinki, Finland) (III) and
differentiated myotubes (III) were used.
6. Primary antibodies
The monoclonal CSTB 2E7 antibody against purified human CSTB protein produced
in study III and the commercial polyclonal CSTB antibody (Biogenesis) were used in
various experiments (III, IV, this thesis). As organelle markers we used polyclonal
antibodies against protein disulphide isomerase (PDI) from StressGen
Biotechnologies and trans-Golgi network protein 46 (TGN46) from Serotec;
mammalian secretory protein 13 (mSec13) (kindly provided by Wanjin Hong, The
National University of Singapore, Republic of Singapore), mannose-6-phosphate
receptor (MPR) (Kurt von Figura, University of Göttingen, Germany),
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aspartylglucosaminidase (AGA) (Anu Jalanko, National Public Health Institute,
Finland) and lysosome-associated membrane protein 1 (LAMP1, lgp120) (Peter van
der Sluijs, University Medical Center Utrecht, the Netherlands). In addition, FITC-
labelled Lentil lectin was from Sigma and LysoTracker® Green DND-26 from
Molecular Probes.
7. Methods
The methods used in the published papers and in the unpublished experiments
included in this thesis are summarized in Table 5.
Table 5. Methods used.
METHODS PUBLICATION
Recombinant DNA techniques (cloning) I II III IV this thesis
DNA extraction I II III IV this thesis
PCR (polymerase chain reaction) I II III IV this thesis
DNA sequencing I II III IV this thesis
Computer sequence analysis (BLAST, RepeatMasker, Primer 3,
MatInspector, ASAP, AceView)*, (Sequencer 4.0, Primer Express)
I II III IV this thesis
Northern blot analysis I II IV
Cell culture I III IV this thesis
Transient DNA transfections I III IV this thesis
RNA isolation I IV
Luciferase and β-galactosidase activity assay I
Electrophoretic mobility shift assay (EMSA) I
Radioactive RNA in situ hybridization II this thesis
Computer-based MCID image analysis II
DIG-labelled RNA in situ hybridization (in whole-mount embryos) II
Production of monoclonal antibodies II III this thesis
Quantitative real-time RT-PCR II IV
Semi-quantitative RT-PCR this thesis
Site-directed mutagenesis III this thesis
In vitro translation (IVT) III this thesis
Immunoprecipitation III this thesis
Protein extraction III IV this thesis
Western blot analysis III IV this thesis
ECL (enhanced chemiluminiscence) III IV this thesis
Immunofluorescence stainings III IV this thesis
Immunofluorescence microscopy III IV this thesis
Dark- and bright-field microscopy II
Patient mutation analysis IV
* BLAST (http://www.ncbi.nlm.nih.gov/BLAST/), RepeatMasker (http://www.repeatmasker.org/), Primer 3
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), MatInspector (http://www.genomatix.de/matinspector.html), ASAP
(http://www.bioinformatics.ucla.edu/ASAP/), AceView (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/).
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RESULTS AND DISCUSSION
1. Novel patient mutations (IV)
Two novel EPM1 mutations, c.149G>A and c.168+1_18del, in the CSTB gene were
identified in compound heterozygous form with the dodecamer repeat expansion in
two newly clinically diagnosed patients (IV). None of the 166 controls tested carried
these mutations. The expansion mutations in these patients were verified with the
novel PCR protocol (IV, Fig. 2), which allows direct reliable detection of expanded
CSTB alleles.
The novel missense c.149G>A mutation was identified in a Finnish EPM1
patient. It resulted in substitution of glycine by glutamic acid at amino acid position
50 (p.Gly50Glu) (IV, Fig. 3A). This mutation is situated in the highly conserved
QVVAG sequence critical for papain binding (Stubbs et al., 1990). No mutation
affecting this pentapeptide has previously been identified. The p.Gly50Glu mutation
seems to be translated in patient cells (see below, section 4.2) and is likely to affect
the stability or life span of the inhibitory effect of the protein, or the interactions with
target proteins (Jerala et al., 1990; Auerswald et al., 1995). That EPM1 results from a
mutation in this site implies the physiological importance of cathepsin binding.
The second novel mutation, observed in an Italian EPM1 patient, is a deletion
of the first 18 nucleotides downstream from the 5’ splice donor site of intron 2
(c.168+1_18del) (IV, Fig. 3B). On the mRNA level, this mutation results in aberrant
splicing of CSTB with production of two different transcripts (IV, Fig. 3C). The
shorter transcript has an in-frame deletion of exon 2 and predicts a deletion of a 34
amino acid region containing the QVVAG sequence, creating a p.delVal23_Lys56
polypeptide. The longer transcript contains 25 nucleotides from intron 2 resulting in a
frameshift and predicting a premature stop codon (p.Val57GlufsX28). It remains,
however, unknown whether these transcripts are translated or whether the gene
products are degraded after transcription, e.g. due to nonsense-mediated-decay. The
p.delVal23_Lys56 protein was not detected in vitro or in vivo (see below, section 4.2).
46 Kirsi Alakurtti
2. Characterization of the CSTB gene
2. 1. The CSTB promoter and its transcriptional elements (I)
To characterize the CSTB promoter the 5’ genomic sequence of CSTB was extended
by 3051 bp by primer walking from the previously published sequence (Pennacchio et
al., 1996). An Alu-rich region at -1782 to -686 bp upstream of the translation
initiation codon was identified and further characterization was limited downstream of
it. The sequence analysis revealed many similarities with a typical housekeeping gene
promoter with a high GC-content (75%), a high number of CpG dinucleotides and the
presence of several Sp1 binding sites. The promoter region of the cystatin C gene
(abbreviated CST3) shares these features (Abrahamson et al., 1990), whereas the
CSTA promoter has a low GC-content (36%) and lacks putative Sp1 binding sites
(Takahashi et al., 1998). All three promoters lack CAAT and TATA boxes. The
nucleotide sequence of the putative CSTB promoter region was analyzed with the
MatInspector program to identify putative transcriptional elements. In addition to the
previously published five putative Sp1 sites (Pennacchio et al., 1996), four putative
AP1 sites, an androgen response element (ARE) half site and a MyoD site were
identified (I, Fig. 1A). The minimal functional promoter was mapped using promoter-
reporter gene constructs containing three different genomic fragments from -670
(construct 1), -228 (construct 2) and -145 (construct 3) to -1 bp upstream of the
translation initiation codon (Fig. 4; I, Fig. 1B).
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Figure 4. The CSTB gene and its putative promoter region. On the top is shown the genomic structure
of the CSTB gene with its three exons. The enlarged view shows the CSTB promoter region with a
putative androgen response element (ARE) half site, a potential MyoD element, four AP1 and five Sp1
sites. The three PstI (Ps), a BsshII (B) and a PmlI (Pm) restriction endonuclease cleavage sites are
indicated below the black bar. Construct 1 from -670 to -1 bp, construct 2 from -228 to -1 bp and
construct 3 from -145 to -1 bp were cloned into the pGL3-Basic vector containing the luciferase-
reporter (LUC) gene. Construct 4 contains the region -670 to -1 bp and has 16 extra copies (19 copies
in total) of the dodecamer repeat. Construct 5 contains regions -670 to -514 bp and -411 to -1 bp, and
lacks the region containing two AP1 sites and the MyoD element. Constructs 1, 2 and 5 contain three
dodecamer repeat copies. Picture from publication I.
The promoter activity of construct 3 containing two potential Sp1 sites and
one AP1 site was over 40 times, of construct 2 with three additional Sp1 sites
approximately 60 times, and of construct 1 with the addition of three AP1, one MyoD
and one ARE sites about 300 times the activity of the empty luciferase construct (I,
Fig. 2). The activity of the promoter was orientation-dependent, since constructs 1 (I,
Fig. 2), 2 and 3 (I, data not shown) showed less activity in reverse than in forward
orientation. Construct 5 without two AP1 sites and a MyoD element, lacking
nucleotides -514 to -411 bp from construct 1, reduced the promoter activity by 30%
(I, Fig. 2), suggesting that these sites are involved in the regulation of CSTB
transcription. The sequence from -670 to -229 bp seems to contain strong activator
elements as the activity of construct 1 was five times that of construct 2. These data
suggested that the region between -670 and -1 bp from the translation initiation codon
acts as the promoter of the CSTB gene. Studying a 3.2 kb promoter construct in four
different cell lines (SK-N-BE, CHP [both derived from human neuroblastomas], HeLa
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[derived from cervical cancer cells] and COS-7), Lalioti et al. (1999) detected at least
a 100-fold increase in promoter activities when compared to a construct without a
promoter. Our higher, 300-fold, increase in promoter activity could be explained by
the very different lengths of promoter constructs and/or the different cell lines used
(in our assays COS-1 cells).
DNA-protein interaction assays with four AP1 and five Sp1 sites as well as an
ARE half site were performed by electrophoretic mobility shift assays (EMSAs). The
interaction of the MyoD site was not studied. The tandem AP1 site at -480 to -469 bp
(I, Fig. 3), as well as the AP1 sites at -316 to -313 bp (I, Fig. 3) and -83 to -79 bp (I,
data not shown) were capable of forming complexes with c-Jun. The Sp1 sites at -107
to -86 bp, -120 to -99 bp and -210 to -175 bp formed complexes with purified human
Sp1 protein (I, Fig. 4). Sp1 proteins bound particularly strongly to the oligonucleotide
of Sp1 site at -210 to -175 bp containing three copies of the Sp1 element (I, Fig. 4),
which are part of the sequence in the dodecamer repeats. Similarly, the CST3 gene
promoter region at -257 to -211 bp contains three Sp1 binding sites that are thought to
play a major role in transcription (Olafsson, 1995). The CST3 promoter contains 11
possible Sp1 binding sites, but only one AP1 site (-970 to -960 bp) (Olafsson, 1995).
Binding of androgen receptor (AR) to the ARE half site appeared to be relatively
weak as it was only recognized in the presence of an AR stabilizing antibody (I, Fig.
5). A similar ARE sequence is found in the mouse Cst3 gene (Huh et al., 1995), but
not in the human CST3 or CSTA genes (Abrahamson et al., 1990; Takahashi et al.,
1998). Two Sp1/GC, one AP2 and one AP1 transcription binding sites are found in
human, mouse and rat CSTB promoter regions (Lalioti et al., 1999).
In conclusion, the region between -670 to -1 bp from the translation initiation
codon is suggested to induce the basal activity of CSTB  expression and all
transcription binding sites studied were found to be capable of binding in vitro to
sequence-specific factors.
2. 2. Expression of the Cstb and CSTB genes
Previously, the CSTB gene had been found to be ubiquitously expressed in adult
human and mouse tissues (Pennacchio et al., 1996; Pennacchio and Myers, 1996). The
clinical manifestations of EPM1 seem to be limited to the CNS. In order to assess the
potential cellular specificity of CSTB expression, the spatial and temporal expression
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of Cstb in mouse embryos and adult mouse tissues, with special emphasis on the
brain, was characterized in more detail.
2.2.1. Tissue expression (II, IV)
The tissue expression of Cstb in various mouse fetal and adult tissues was first studied
with Northern blot analysis and quantitative real-time PCR. With both methods, a
strikingly high level of Cstb expression was detected in E7 embryos (II, Fig. 1A, B).
In real-time PCR analysis the level of Cstb  expression in E7 embryos was
approximately twenty times higher than the mean expression in other developmental
stages studied (II, Fig. 1B). In Northern blot analysis highest expression in adult
tissues was detected in thymus (II, Fig. 1A). In the quantitative real-time analysis, in
which the commercial panel we used lacked thymus, highest expression was detected
in kidney, liver and lung (II, Fig. 1B). Interestingly, the expression in brain was
among the lowest (II, Fig. 1A, B). In a parallel study, CSTB expression in human fetal
and adult tissues was quantitated using real-time PCR. CSTB was ubiquitously
expressed, being highest in lung and relatively low in brain (IV, Fig. 4A), a pattern
very similar to that seen in mouse (II).
2.2.2. Spatial expression in mouse embryos and postnatal brain (II,
unpublished)
The strikingly high levels of Cstb in the E7 embryos in the Northern blot and
quantitative real-time PCR analyses prompted us to study the spatial expression of
Cstb during early mouse embryogenesis by whole-mount RNA in situ hybridization.
These studies were continued using cryosections of embryos during late
embryogenesis as well as of postnatal mouse brains, where the EPM1 symptoms
manifest.
The expression of Cstb was intense and uniform in the entire E7 and E8 mouse
embryos, but was not detected in extraembryonal tissues (II, Fig. 2A, C).
Interestingly, cathepsins are expressed in the extraembryonal tissues at this stage (Sol-
Church et al., 1999). Highest Ctsl activity is detected in visceral yolk sac and highest
Ctsl mRNA levels in placenta of E9.5 embryos (Sol-Church et al., 1999). Expression
of Ctsb mRNA in placenta increases gradually from E7.5 to E17.5 embryos (Sol-
Church et al., 1999). In E9.5 and E10.5 embryos Cstb expression has been reported in
brain, spinal chord, eye, otocyst, dorsal root ganglia, branchial arches, heart, gut,
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kidney, limbs and skin (Reymond et al., 2002). Cstb has been included in a cluster of
genes which by EST mining are expressed in the total fetus (Gitton et al., 2002).
The Cstb localization in later embryogenesis was studied using radioactive
RNA in situ hybridization in sectioned E14 and E17 embryos. In E14 and E17
embryos quantification with a computer-based MCID image analysis system revealed
strongest Cstb expression in thymus (II, Fig. 3A, C; Fig. 5B), concordant with high
thymic expression detected in Northern blot analysis (II, Fig. 1A). In line with these
findings, relatively strong expression of Cstb in thymus at this stage has earlier been
reported (Reymond et al., 2002). Interestingly, the targets of CSTB, cathepsins, have
been implicated to have a role in immune response through processing functions in
mammalian antigen-presenting cells (reviewed in Zavasnik-Bergant and Turk, 2006).
Moreover, Tt-cysb, the leech Theromyzon tessulatum homologue of mammalian
CSTB, has been shown to become up-regulted after immunostimulation with a
bacterial challenge, implying a role for Tt-cysb in leech innate immunity (Lefebvre et
al., 2004).
Cstb expression in E14 and E17 embryos was detected in several tissues in
addition to thymus with a restricted cellular expression pattern. Cstb was expressed in
several epithelial layers such as in the nasopharyngeal epithelium (Fig. 5C; II, Fig.
3D), pharynx and tracheal epithelium (II, data not shown), epithelium lining the
intestine (Fig. 5F; II, Fig. 3H) and epithelium of the skin (II, data not shown).
Concordant with these findings, Reymond et al. (2002) have earlier reported Cstb
expression in skin and intestine in E14.5 embryos. Interestingly, Cathepsin L-like
cysteine protease (CPL-1) in Caenorhabditis elegans is highly expressed in gut cells
during late embryonic development (Hashmi et al., 2002). The intestinal mucosa is
known to play an important role in mucosal and systemic immune response (Muller et
al., 2005), and it is possible that Cstb is also linked to this kind of immune response
through regulation of cathepsin activity. Cstb was expressed in the neopallial cortex
(future cerebral cortex) (Fig. 5A; II, Fig. 3A, B). Expression was observed in certain
parts of the lower incisor tooth in outer enamel epithelium (Fig. 5D; II, Fig. 3E) and
in maxilla (Fig. 5D; II, Fig. 3E) and mandible (II, Fig. 3F), as well as in vertebra bone
forming cells (Fig. 5E; II, Fig. 3G). Cstb expression in developing bone (Fig. 5D, E;
II, Fig. 3E-G) is in line with recent findings of CSTB having regulatory functions in
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osteoclasts, where it could inhibit bone resorption by down-regulating intracellular
CTSK activity (Laitala-Leinonen et al., 2005).
Figure 5. Cstb expression in E17 mouse embryos. Cstb hybridization signals visualized in neopallial
cortex (future cerebral cortex) (A), thymus gland (B), nasopharyngeal epithelium, while the olfactory
epithelium is negative (indicated by an arrow) (C), primordium of lower incisor tooth in outer enemal
epithelium (shown by an arrow) (D), mandible (D), vertebra bone forming cells (E) and epithelium of
the intestine (F). The dark-field images, that were inverted and stained red, are combined with the
bright-field images presenting hematoxylin staining. Magnification is 50X. Picture modified from
publication II.
In postnatal mouse brain the pattern of the Cstb expression was restricted. In
P1 and P5 mouse brain sections Cstb was expressed in cortex, caudate putamen,
hippocampus and thalamus (II, Fig. 4A, B; Fig. 6A). Expression, as determined by
relative optical density levels, was higher at P1 than at P5 (II, Fig. 4A). The cortical
expression seen in P1 and P5 mouse brains (II, Fig. 4A, B; Fig. 6A) is in line with the
Cstb-deficient mice having cortical neuronal atrophy, neuronal apoptosis and gliosis
(Shannon et al., 2002). In hippocampus, Cstb expression was seen in the CA1, CA2
and CA3 pyramidal cell layers and in the dentate gyrus granule cell layer (Fig. 6A-C;
II, Fig. 4A-D), compatible with Cstb-deficient mice having neuronal apoptosis and
gliosis in the hippocampal formation (Shannon et al., 2002). In line with our results
are findings of Cstb mRNA expression in the rat, where expression was highest in the
hippocampal formation and reticular thalamic nucleus, and moderate in the amygdala,
thalamus, hypothalamus and cortical areas (D'Amato et al., 2000).
In the cerebellum Cstb expression was most prominent in the Purkinje cell
layer in P21 (Fig. 6D; II, Fig. 4E, F) and adult mice brains (II, data not shown). Cstb
expression in granule and molecular cell layers seems to be much weaker (Fig. 6D; II,
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Fig. 4E, F), though the overall signal in the cerebellum could not be quantitated with
the MCID image analysis system (II, data not shown). Concordant with the high
expression in Purkinje cells, EPM1 patients have been reported to have loss of
Purkinje cells, which might, however, been attributed to the use of phenytoin (Haltia
et al., 1969; Koskiniemi et al., 1974a; Eldridge et al., 1983). This view is supported by
the findings in Cstb-deficient mice that have not been exposed to medication and that
display only occassional loss and ballooning of Purkinje cells, indicating that Cstb-
deficiency per se can cause loss of these cells, although to a lesser extent (Shannon et
al., 2002). In light of high Cstb expression in Purkinje cells the striking granule cell
loss seen in the Cstb-deficient mice could be secondary to the dysfunction of Purkinje
cells (Riccio et al., 2005).
Figure 6. Cstb expression in postnatal mouse brain. (A) In frontal P5 brain section Cstb expression is
seen in cortex (Ctx), caudate putamen (CPu), hippocampus (Hc) and thalamus (Th). In fronal P1 (B)
and P5 (C) sections Cstb is detected in hippocampal regions CA1, CA3 and dentate gyrus (DG). (D) In
sagittal P21 section expression is prominent in the Purkinje cell layer (PCL) of cerebellum. GL,
granular layer. ML, molecular layer. Magnification is 25X in A, 50X in B, C and 100X in D. Modified
from publication II.
In conclusion, Cstb expression seems to be under tight temporal and spatial
regulation. Cstb is widely expressed throughout embryonic development, with highest
expression in E7 embryos as well as in the embryonic and adult thymus, and epithelial
layers of several tissues. In the CNS Cstb expression is highly restricted in
concordance with the clinical presentation and limited neuronal pathology in humans
and mice. Outside the CNS CSTB inhibitory activity seems to be functionally
redundant, as there are no consistent developmental or non-neuronal phenotypes in
EPM1 patients and Cstb-deficient mice.
We aimed to investigate the tissue distribution of the Cstb protein using
immunohistochemical analysis. These studies were impossible to conduct, since
despite several attempts we were unable to produce a specific monoclonal or
polyclonal antibody recognizing the mouse Cstb protein. The commercially available
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polyclonal antibody against human CSTB that has been used in several studies (Di
Giaimo et al., 2002; Riccio et al., 2005) to recognize mouse and rat Cstb turned out, in
our hands, to be unspecific in immunohistochemical stainings of mouse tissues and
immunofluorescence analysis of mouse cells, as identical staining patterns were
detected in both wild-type and Cstb-deficient mouse brain sections or primary
neuronal cell cultures (data not shown). In Western blot staining this antibody seemed
to be specific, since the Cstb protein was not detected from Cstb-deficient mouse
brain extracts (data not shown). However, in addition to the Cstb-specific band, the
antibody recognized several larger molecular mass proteins from wild-type and Cstb-
deficient mouse brain extracts (data not shown). The analysis of Cstb protein
expression in tissues still awaits a specific, working antibody.
2. 3. Splice variants and their expression (IV, unpublished)
Approximately 60% of human genes and at least 41% of mouse genes have
alternatively spliced transcripts, resulting in the large number of proteins with
different functions or tissue-specificities (Lander et al., 2001a; Okazaki et al., 2002).
The number of tissue-specific splice variants is highest in brain, where they are
involved in the development and differentiation of the CNS, and in controlling
neuronal activity (Grabowski and Black, 2001; Xu et al., 2002). Alternative splicing
of CSTB was suggested in the databases (ASAP and AceView). Human CSTB and
mouse Cstb splice variants were isolated by in silico analysis and with RT-PCR, and
were further characterized with various methods.
In addition to the normal CSTB splice form, a CSTB2 splice variant was
assembled, as well as CSTB3, CSTB4 and CSTB5 splice variants were identified (IV).
Full assembly of the latter three variants was impossible, since amplification from the
5’ end favored the CSTB isoform (IV). Moreover, expression of the CSTB3, CSTB4
and CSTB5 transcripts was restricted to colon, intestine and prostate (IV, data not
shown), and therefore were thought to have no significance for EPM1 pathogenesis.
The CSTB2 transcript was ubiquitously expressed, also in brain. In this transcript
intron 2 sequences are retained, and the putative CSTB2 protein is encoded from
exons 1 and 2 and from intron 2 sequences containing a stop codon after 78 bp,
creating a putative 83 amino acid protein. In Northern analysis, CSTB2 was expressed
at very low levels in all adult and fetal tissues studied (data not shown). In
quantitative real-time PCR, human CSTB2 was expressed in all fetal and adult tissues
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examined, being highest in lung and thymus in fetal, and in lung in adult stages (IV,
Fig. 4B). The proportion of CSTB2 ranged from about 0.4% to approximately 5% of
the expression of all CSTB transcripts, depending on the tissue examined (IV, Fig.
4C). The mouse Cstb2 was PCR-amplified from mouse brain and testis with an open
reading frame of 192 bp predicting a 64 amino acid Cstb2 protein (IV). Cstb2 was
expressed ubiquitously at low levels in all developmental stages and adult mouse
tissues examined (Fig. 7). RNA in situ hybridization did not detect Cstb2 mRNA
expression in mice embryos, or in postnatal or adult mouse brain slices (data not
shown), implying very low expression. These data show that CSTB2 and Cstb2 are
both expressed ubiquitously at low levels.
Figure 7. Semi-quantitative expression analysis of Cstb2 in a Clontech mouse MTC panel, containing
mouse adult tissues and whole mouse embryos at E7, E11, E15 and E17. The results at 34 cycles of
amplification are shown. Mouse glyceraldehyde-3-phosphate dehydrogenase (Gapdh) gene expression
at 26 cycles is shown as a control in the lower panel. Cstb2 expression was detected in all adult mouse
tissues and embryonal stages studies (unpublished).
3. Characterization of the CSTB protein (III)
3. 1. Production of a CSTB-specific monoclonal antibody
A monoclonal antibody against CSTB purified from human muscle and spleen was
raised in study III. The 2E7 antibody recognized a protein of approximately 12 kDa,
the calculated molecular weight of CSTB, in Western blots of COS-1 cell lysates and
control lymphoblastoid cells (Fig. 8B; III, Fig. 1). The 2E7 antibody did not
crossreact with the homologous CSTA protein (for protein sequence similarities with
CSTB see Fig. 8A) in Western analysis (Fig. 8B; III, Fig. 1) or in ELISA (III, data not
shown). Epitope mapping (III, data not shown) revealed amino acids 31 to 39 of the
CSTB sequence as the epitope for the 2E7 antibody (Fig. 8A; III). The sequence in
the corresponding region of CSTA is different (with the exception of one amino acid,
Fig. 8A; III), giving proof of the specificity of the 2E7 antibody. In addition, in
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Western blot analysis of lymphoblastoid cells of EPM1 patients homozygous for the
repeat expansion mutation or compound heterozygous for the repeat expansion and
c.202C>T nonsense mutations no CSTB protein was detected (Fig. 8B; III, Fig. 1),
further proving the specificity of the 2E7 antibody.
A
B
Figure 8. Specificity of the monoclonal CSTB antibody. (A) CSTB is closely related to CSTA and the
amino acid sequence identity between CSTB and CSTA is 53%. The epitope recognized by the
monoclonal CSTB antibody 2E7 is underlined. (B) The 2E7 antibody detected CSTB in COS-1 cells
(1) and control lymphoblastoid cells (2). CSTB protein was not detected in lymphoblastoid cells of an
EPM1 patient homozygous for the repeat expansion mutation (3) or of a patient compound
heterozygous for the repeat expansion and c.202C>T (p.Arg68X) mutations (4). The antibody
recognized purified CSTB (5), but not purified CSTA (6). Picture B modified from publication III.
3. 2. Cellular localization of endogenous CSTB protein
CSTB has been thought to be a soluble cytoplasmic protein (Stubbs et al., 1990).
Recent evidence had shown that within cells CSTB is localized in the nucleus and in
cytoplasmic granular structures, representing either the Golgi complex or lysosomes
(Calkins et al., 1998; D'Amato et al., 2000; Riccio et al., 2001). We further aimed to
determine the cellular compartments where endogenous CSTB resides using the novel
monoclonal 2E7 antibody and organelle marker antibodies in immunofluorescence
analysis.
In addition to cytoplasm, endogenous CSTB protein was found to reside in
two intracellular compartments in COS-1 cells and human primary myoblasts (Fig.
9A-D; III, Fig. 2). To optimally visualize CSTB in different cellular pools detergents
with different permeabilization properties were used. Triton X-100 was used to
visualize both nuclear and cytoplasmic pools, and saponin the cytoplasmic pool, as it
does not permeabilize the nuclear envelope. In COS-1 cells and proliferating
myoblasts, CSTB localized prominently to the nucleus (Fig. 9A; III, Fig. 2A, B). In
MMCGAPSATQ PATAETQHIA DQVRSQLEEK ENKKFPVFKA VSFKSQVVAG TNYFIKVHVG
:  :  :    ::: : : :  : :  :::::  :       : :  : ::::: ::: :::  :
MIPGGLSEAK PATPEIQEIV DKVKPQLEEK TNETYGKLEA VQYKTQVVAG TNYYIKVRAG
DEDFVHLRVF QSLPHENKPL TLSNYQTNKA KHDELTYF    CSTB
:    :: ::  :::  :  :  :  ::  :  : :::: :
DNKYMHLKVF KSLPGQNEDL VLTGYQVDKN KDDELTGF    CSTA
56 Kirsi Alakurtti
addition, CSTB was visible diffusely and in punctate structures in the cytoplasm (Fig.
9C; III, Fig. 2D, E). In differentiated myotubes, CSTB was localized mainly in the
cytoplasm and excluded from the nucleus (Fig. 9B; III, Fig. 2C). In COS-1 cells and
myoblasts numerous punctate cytoplasmic structures were observed (Fig. 9C; III, Fig.
2D, E), while in myotubes the number of these structures was decreased (Fig. 9D; III,
Fig. 2F). On the basis of these results, it seems that the subcellular distribution of
CSTB is dependent on the differentiation status of the cell. This is in agreement with
previous findings in which CSTB was found in the nucleus in proliferating neuronal
cells and in the cytoplasm in differentiated human neuroblastoma and rat primary
cerebellar granule cells (Riccio et al., 2001).
Figure 9. Subcellular localization of endogenous CSTB protein. Cells were permeabilized with TX-
100 (A, B) or saponin (does not permeabilize the nuclear envelope) (C-G). In myoblasts CSTB
localizes to the nucleus, cytoplasm and punctate cytoplasmic structures (A, C). In differentiated
myotubes (shown by arrows) CSTB is localized to the cytoplasm and excluded from the nucleus and
punctate cytoplasmic structures (B, D). CSTB-positive punctate cytoplasmic structures colocalized
with the lysosomal marker AGA (E-G). Picture modified from publication III.
To identify the CSTB-positive punctate cytoplasmic structures different
organelle markers were used. No overlap was observed with CSTB and markers for
the endoplasmic reticulum (PDI), ER exit site (mSec13), Golgi (Lentil lectin), trans-
Golgi network (TGN46) or late endosomes (MPR) (III, Fig. 3A-E). Instead, the CSTB
protein displayed significant overlap with the lysosomal enzyme,
aspartylglucosaminidase (AGA) (Fig. 9E-G; III, Fig. 3F). Many but not all AGA-
positive structures stained with the CSTB antibody, indicating that CSTB associates
only with a subset of lysosomes. In COS-1 cells similar colocalization of endogenous
CSTB was observed, as CSTB colocalized with the AGA marker but not with other
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cellular markers (III, data not shown). The lysosomal association of CSTB is in line
with the current view of CSTB having a protective role as a cytoplasmic inhibitor of
cysteine proteases released from lysosomes, and this view was further supported by
the decreased cerebellar granule cell apoptosis detected in Cstb- and Ctsb-double-
deficient mice (Houseweart et al., 2003a). CSTB could also be involved in signaling
events involved in e.g. apoptosis with downstream effects on transcriptional
regulation, because it was found to localize both in the cytoplasm and nucleus in
addition to lysosomes.
3. 3. Biochemical properties of the CSTB protein
Whether the CSTB protein localizes inside or outside of lysosomes, and whether it is
transported out of the cells, were investigated with immunoprecipitation of in vitro
translated CSTB or endogenous CSTB from COS-1 cells.
In vitro translated CSTB was not enriched in microsomes, as was shown when
the membranes were added co- or posttranslationally, but instead remained largely in
the supernatants (III, Fig. 4A). This indicates that CSTB was unable to translocate
into microsomal membranes. As a control, we used the soluble lysosomal enzyme
(AGA) and an integral membrane protein (p58/ERGIC-53) that, as expected,
translocated through or integrated in microsomal membranes, respectively (III, data
not shown). In Western blot analysis CSTB could be immunoprecipitated from the
COS-1 cell lysate but not from the culture medium (III, Fig. 4B), indicating that
endogenous CSTB is not secreted in significant amounts in this cell type. CSTB was
not detected in the cellular compartments of the early secretory pathway even when
overexpressed (III, data not shown). These results, together with the fact that CSTB
lacks an ER signal sequence, suggest that CSTB is attached to the outer side of the
lysosomal membrane rather than residing within the lysosome. This hypothesis should
be confirmed experimentally, for example by immunoelectronmicroscopy. However,
it is tempting to speculate that the localization of CSTB to the lysosomal membrane is
mediated through binding to cathepsins that are leaking out of the lysosomes. This
speculation gets further support from the analysis of missense mutant CSTB proteins
(see below, section 4.2) that are predicted to disturb cathepsin binding and that lose
the lysosomal association.
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4. CSTB gene and CSTB protein expression in EPM1 patients
4. 1. Effect of EPM1 mutations on CSTB gene expression (I, IV, unpublished)
To study the effect of the dodecamer repeat expansion on the expression of CSTB,
three different approaches were used. First, we evaluated the promoter activity in vitro
using promoter constructs containing wild-type and expanded alleles. Second, using
Northern blot analysis we studied the mRNA levels in lymphoblastoid cells of
individuals with “premutation” repeat expansions and of EPM1 patients homozygous
for the full length repeat expansion. Third, using quantitative real-time PCR analysis
we measured the mRNA levels in lymphoblastoid cells and fibroblasts of patients
homozygous for the repeat expansion as well as compound heterozygous for the
repeat expansion and some other EPM1 mutation.
In the luciferase reporter gene assays the addition of 16 dodecamer repeats to
the luciferase-CSTB construct 1 (Fig. 4, section 2.1), creating construct 4, lowered its
activity 10-fold in COS-1 cells (I, Fig. 2). This indicates that the repeat expansion
significantly reduces the normal transcription in vitro. We were unable to obtain the
“disease-length” expansions in the promoter reporter constructs, due to the unstable
nature of the dodecamer repeat expansion (Lalioti et al., 1997b; Virtaneva et al.,
1997). We could generate only a “premutation” length expansion construct containing
19 repeats (in EPM1 patients more that 30 copies have been reported), however,
already this construct showed a clear reduction of luciferase expression. In another
study, Lalioti et al. (1999) created a longer 3.2 kb promoter construct containing 50
dodecamer copies. They noted that cloning of the expanded promoters in
commercially available luciferase plasmids resulted in instability, but the expansions
were stable in a pbluescript vector. Interestingly, using this construct Lalioti et al.
(1999) found only a two- to fourfold reduction of luciferase activity in SK-N-BE and
HeLa cells. That we detected a 10-fold reduction in luciferase expression could be
partly explained by our significantly shorter construct rather than by the difference in
the expansion lengths, as it would be quite unexpected to see higher transcription with
longer repeat expansions. They also showed reduced promoter activity due to the
expansion in some cell types (Lalioti et al., 1999). The luciferase activity was either
only slightly decreased or increased in CHP and COS-7 cells. Concordant with their
previous finding on CSTB mRNA expression (Lalioti et al., 1997b) (discussed below),
they suggested that the regulation of CSTB expression may be cell specific.
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In Northern blot analysis CEPH individuals with “premutation” length
expansions (Lalioti et al., 1997b) of 12 to 17 copies in both alleles had clearly reduced
CSTB mRNA levels compared to controls, as did carriers with one normal and one
expanded allele (I, Fig. 6). We further analyzed with quantitative real-time PCR the
expression levels in these CEPH individuals. CSTB levels were consistently reduced
in individuals with “premutation” expansions in both alleles, but not in individuals
with one normal and one “premutation” allele (data not shown). These individuals
have not been reported to have symptoms compatible with EPM1, suggesting that the
development of the clinical signs of EPM1 depend on a threshold of CSTB expression.
However, it should be noted that several of these Venezuelan CEPH individuals have
a diagnosis of Huntington’s disease, characterized by chorea and dementia, which
could “mask” signs of EPM1 if not specifically looked for. It is also possible that the
EPM1 symptoms could have a later onset or be milder than with the full length
expansion.
The effect of the EPM1 mutations on CSTB mRNA expression levels was
further studied with quantitative real-time RT-PCR from lymphoblastoid cell RNA of
patients homozygous or compound heterozygous for the repeat expansion. In
homozygous patients CSTB expression was markedly reduced, the mean expression
(± standard deviation) being 8.8% ± 1.0% of the controls (IV, Fig. 5A). CSTB
expression was also similarly reduced compared to controls in fibroblasts of two
homozygous patients (IV, data not shown). The heterozygous expansion mutation
carriers had 60.6% ± 12.7% of the CSTB expression in controls (IV, Fig. 5A).
Compound heterozygotes for the expansion and the c.67-1G>C splice site mutations
the level of CSTB was 17.9% ± 3.8% that of the controls (IV, Fig. 5A). The RT-PCR
primers were designed so that the mutant c.67-1G>C mRNA was not amplified and
the higher expression levels compared to those in patients with homozygous
expansion mutations suggest that the splicing site is leaking (IV). Such partial
penetrance mutations have been reported earlier (Svenson et al., 2001), and that
possibility in relation to this mutation has also been discussed (Bespalova et al.,
1997b). In a patient compound heterozygous for the expansion and the c.202C>T
nonsense mutations, and another for the expansion and the novel c.149G>A missense
mutations, the CSTB mRNA levels were 35.4% ± 4.5% and 15.6% ± 3.8% of controls,
respectively (IV, Fig. 5A).
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Lalioti et al. (1997b) have shown, using an RNase protection assay, that CSTB
was markedly reduced in blood leukocytes (10-20%) whereas it was either normal or
only slightly reduced in lymphoblastoid cells or fibroblasts of EPM1 patients carrying
the expansion. These results are discrepant with our quantitative real-time PCR (IV)
and the Northern blot results (Pennacchio et al., 1996; Lafrenière et al., 1997; Lalioti
et al., 1997b; I), unequivocally showing that all mutations analyzed down-regulate the
expression of CSTB mRNAs. Both our in vitro promoter study (I) and quantitative
real-time PCR (IV) as well as the RNase protection assay in blood leukocytes (Lalioti
et al., 1997b) imply that CSTB mRNA expression is approximately 10% of normal in
patients homozygous for the expansion mutation. The contradictory findings of the
RNase protection assay in other cell lines are intriguing (Lalioti et al., 1997b), but
may be simply due to a more complicated experimental set-up in the assay.
In the CSTB promoter region three Sp1 binding sites, part of the dodecamer
repeats, interacted strongly in vitro with the transcriptional Sp1 activator proteins (I,
Fig. 4). Even if each dodecamer unit contains one Sp1 binding site and an expansion
of these repeats results in an increase of these putatively activating sites, the
consequence of the expansion is down-regulation of transcription (Lalioti et al., 1999;
I). The explanation of this paradox might be that the changes in the chromatin
structure result in disturbed transcriptional machinery or the expansion might be more
prone to bind inhibitory proteins such as Sp3, also known to bind to GC-motifs
(Hagen et al., 1994; see section 6 in the REVIEW OF THE LITERATURE). On the
contrary, Lalioti et al. (1999) speculated that the different spacing of transcription
elements could cause the reduction of CSTB transcription and tested their hypothesis
by substituting the repeat with heterologous fragments of bacterial and mammalian
sequences of similar sizes and showed similar reduction to that observed with the
dodecamer repeat expansion. The dodecamer repeat could also be methylated, which
has not been directly determined, but the CSTB promoter region is not known to be
significantly hypermethylated (Lalioti et al., 1997b; Virtaneva et al., unpublished
data). Our primary hypothesis of altered chromatin structure due to the repeat
expansion as the underlying mechanism for altered CSTB expression got further
support from the studies of Saha and Usdin (2001), who demonstrated that the
dodecamer repeats form a variety of secondary structures and are unique in that
tetraplexes are the only structures likely to form under physiological conditions (Fig.
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2 ,  section 3.3.1 in the REVIEW OF THE LITERATURE). Such stable secondary
structures have been shown to affect transcription and even translation in association
with trinucleotide repeat expansions (Feng et al., 1995; Parsons et al., 1998).
Therefore, it is also likely that these structures are involved in affecting the
transcription of CSTB.
4. 2. Altered localization of mutant CSTB proteins (III, IV, unpublished)
CSTB mRNA expression was known to be reduced due to the repeat expansion
mutation (Pennacchio et al., 1996; Bespalova et al., 1997a; Bespalova et al., 1997b;
Lafrenière et al., 1997; Lalioti et al., 1997b; I; IV). We further investigated the
consequence of four previously reported and two novel EPM1 mutations on the
localization and stability of the CSTB proteins using in vitro translation (IVT),
immunofluorescence staining of exogenously expressed proteins and Western blot
analysis of endogenous CSTB in patient cells.
First we investigated whether all of the mutant CSTB proteins were
recognized with the novel monoclonal 2E7 antibody and/or with the polyclonal CSTB
antibody. For that purpose we performed radioactive IVT using expression vectors of
the mutant proteins and immunoprecipitation with the 2E7 antibody or polyclonal
CSTB antibody. The wild-type, and all three missense mutant proteins, p.Gly4Arg,
p.Gly50Glu and p.Gln71Pro, were immunoprecipitated with the monoclonal 2E7
antibody (Fig. 10). In contrast, the truncated p.Arg68X and p.Leu73fsX3 proteins
could not be immunoprecipitated with the 2E7 antibody (Fig. 10) even though they
contained the epitope recognized by the antibody (Fig. 8, section 3.1), indicating a
change in the conformation of the epitope. The polyclonal CSTB antibody
immunoprecipitated all in vitro translated CSTB proteins (data not shown), except the
p.delVal23_Lys56 protein, which was not detected even though loaded directly from
the IVT reaction to the gel (data not shown).
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Figure 10. In vitro translated [35S] methionine labelled wild-type (wt), p.Gly4Arg, p.Gln71Pro and
p.Gly50Glu CSTB proteins were immunoprecipitated with the 2E7 antibody. The gradient 8-16% SDS-
PAGE gel (Bio-Rad) resolving proteins from 6 to 70 kDa was used to detect also the predicted
truncated (p.Arg68X, p.Leu73fsX3 and p.delVal23_Lys56) 7 kDa proteins (unpublished). The reason
for CSTB proteins (III, Fig. 4A, B) migrating sometimes as doublets in the SDS-PAGE is not known.
We then studied the subcellular localization of overexpressed wild-type and
mutant CSTB proteins in baby hamster kidney (BHK) cells, since no significant
crossreactivity with the hamster protein was observed with the CSTB antibodies used.
Lysosomes were visualized in the first study with LysoTracker Green (III) and in the
second study with polyclonal lpg tail 120 antibody recognizing the lysosomal LAMP-
1 protein in hamster cells (IV). The overexpressed wild-type CSTB displayed similar
distribution to that of endogenous CSTB, as it was detected in the nucleus, cytoplasm
and lysosomes with both the monoclonal 2E7 (Fig. 11A; III, Fig. 5A; IV, Fig. 6A)
and polyclonal CSTB antibodies (Fig. 13A, section 5). The p.Gly4Arg (Fig. 11B; III,
Fig. 5B), p.Gln71Pro (Fig. 11C; III, Fig. 5C) and p.Gly50Glu (Fig. 11D; IV, Fig. 6B)
missense mutant proteins were diffusely localized to the cytoplasm and nucleus, but
no punctate structures overlapping with the lysosomal markers were observed. The
truncated p.Leu73fsX3 protein was seen diffusely in the cytoplasm and nucleus with
no colocalization with the lysosomal marker (III, Fig. 5D). The p.Arg68X protein was
only detectable when expressed in the presence of lactacystin, a proteasomal inhibitor,
indicating rapid degradation of the protein (III, Fig. 5E). In conclusion, all mutant
CSTB proteins studied failed to associate with lysosomes, implying that the
association of CSTB with lysosomes is of physiological importance and that loss of
this association contributes to the molecular pathogenesis of EPM1. It is tempting to
speculate that the lysosomal association of CSTB is mediated through cathepsin
interactions as none of the mutant proteins predicted to alter cathepsin binding
associate with lysosomes. All the missense mutations are known to be located in the
CSTB protein in such places that mutations are suspected to alter the papain binding
affinity (discussed in section 3.3.2 in the REVIEW OF THE LITERATURE, and in
section 1 in RESULTS AND DISCUSSION).
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Figure 11. Subcellular localization of overexpressed wild-type (wt) and mutant CSTB proteins. (A)
Transiently expressed wild-type CSTB localizes similarly to that of endogenous CSTB, to the nucleus,
cytoplasm and lysosomes. The p.Gly4Arg (B), p.Gln71Pro (C) and p.Gly50Glu (D) mutant proteins are
localized to the nucleus and cytoplasm, but no overlap with the lysosomal markers LysoTracker or
LAMP-1 is detected. Pictures modified from publications III and IV.
Finally, we investigated using Western blot analysis whether the mutant CSTB
proteins are present in lymphoblastoid cells of EPM1 patients. In the first study the
2E7 antibody was used in Western blot analysis (Fig. 8B, section 3.1; III, Fig. 1). In
the second study we used the polyclonal CSTB antibody (IV, Fig. 5B), since it was
noted that in immunofluorescence staining (III, data not shown) and
immunoprecipitations (Fig. 10) that the 2E7 antibody did not recognize the truncated
CSTB proteins. In an EPM1 patient homozygous for the expansion mutation the
CSTB protein amount was significantly decreased (Fig. 8B; III, Fig. 1; IV, Fig. 5B),
concordant with the reduction of mRNA expression (Pennacchio et al., 1996;
Bespalova et al., 1997a; Bespalova et al., 1997b; Lafrenière et al., 1997; Lalioti et al.,
1997b; I; IV). In a patient compound heterozygous for the repeat expansion mutation
and c.202C>T mutation, predicting a truncated p.Arg68X protein, the protein amount
was clearly decreased (Fig. 8B; III, Fig. 1; IV, Fig. 5B). Interestingly, the mRNA
levels (35.4% ± 4.5%) detected in this patient were among the highest in patients (IV,
Fig. 5A), while the protein amount (IV, Fig. 5B) was among the lowest, giving further
proof that the p.Arg68X protein is also rapidly degraded in vivo. Using a circular
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dichroism spectra, the p.Arg68X protein has been shown not to be folded in vitro like
the wild-type CSTB protein (Rabzelj et al., 2005). In addition, the unfolded p.Arg68X
protein was highly prone to aggregate and form amyloid fibrils (Rabzelj et al., 2005),
laying the basis for the suggestion that fibril formation might contribute to the
pathogenesis of EPM1 (Ceru et al., 2005). This hypothesis is discrepant with our in
vitro and in vivo results (Fig. 8B, section 3.1; III, Fig. 1; III, Fig. 5E; IV, Fig. 5B), and
it is likely that the p.Arg68X protein is degraded before it aggregates or forms
amyloid fibrils. In contrast, the p.Gly4Arg protein was shown to be folded like the
wild-type CSTB protein (Rabzelj et al., 2005). Unfortunately we did not have an
opportunity to measure the mRNA or protein levels of this Moroccan EPM1 patient
since no sample was available. In the patient compound heterozygous for the repeat
expansion and the c.149G>A mutation, resulting in a p.Gly50Glu protein, a slight
decrease in the amount of the CSTB protein, attributable to the reduced expression
from the expansion allele, was observed (IV, Fig. 5B). The amino acid changes in the
QVVAG pentapeptide have been speculated to affect the stability or life span of the
inhibitory effect of the protein, or the interactions with their target proteins (Jerala et
al., 1990; Auerswald et al., 1995). The p.Gly50Glu protein stability seems not to be
affected (Fig. 11D; IV, Fig. 5B; IV, Fig. 6B), while the interactions with the target
proteins might be affected since at least association with lysosomes has been lost (Fig.
11D; IV, Fig. 6B). In the EPM1 patient compound heterozygous for the repeat
expansion and the c.67-1G>C mutation, resulting in an in-frame deletion of the entire
exon 2 and a 34 amino acid shorter p.delVal23_Lys56 protein, no protein was
detected (IV, Fig. 5B). The p.delVal23_Lys56 protein was also not detected when
loaded directly from the IVT reaction to the gel (data not shown) or in
immunofluorescence staining even in the presence of lactacystin, the proteasomal
inhibitor (IV, data not shown). These findings indicate that the p.delVal23_Lys56
protein is highly unstable.
5. Characterization of the CSTB2 protein (IV, unpublished)
The CSTB2 protein, putatively translated from the CSTB2 splice variant, is predicted
to be a 9 kDa protein of 83 amino acids, including 57 identical amino acids to CSTB
followed by 26 amino acids encoded by the sequence of intron 2 (IV). CSTB2 was
expressed at very low levels compared to CSTB in human tissues (IV, discussed in
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section 2.3). The CSTB2 mRNA levels in lymphoblastoid cells of EPM1 patients and
controls could not be reliably measured due to inter-assay variation (IV). Instead, in
the fibroblasts of two patients homozygous for the repeat expansion mutation
similarly reduced levels of CSTB and CSTB2 compared to controls were detected,
implying that the expression is regulated by the same promoter (IV, data not shown).
The biological properties of CSTB2 were investigated to evaluate the potential role of
this splice variant in EPM1 pathogenesis.
We first tried to investigate whether CSTB2 is translated in vivo. CSTB2
protein was not visible, due to the expected small amount compared to CSTB, in
Western blot analysis with the 2E7 antibody or polyclonal CSTB antibody (data not
shown). Furthermore, despite repeated attempts a specific antibody for CSTB2, not
recognizing CSTB, could not be produced. Thus the presence of endogenous CSTB2
could not be verified, and we therefore decided to study the stability of in vitro
translated CSTB2. In vitro translated wild-type, p.Gly4Arg and p.Gly50Glu CSTB2
proteins were stable and could be immunoprecipitated with the polyclonal CSTB
antibody (Fig. 12), but not with the 2E7 antibody (data not shown).
Figure 12. In vitro translations of CSTB2. SDS-PAGE gels of in vitro translated wild-type (1),
p.Gly4Arg (2) and p.Gly50Glu (3) CSTB2 proteins. IVT followed by immunoprecipitation using the
polyclonal CSTB antibody: wild-type (5), p.Gly4Arg (6) and p.Gly50Glu (7) proteins are
immunoprecipitated in equal amounts. An empty pcDNA3.1(+) expression vector was used as a
negative control (4, 8) (unpublished). The reason for CSTB (Fig. 10; III, Fig. 4A, B) and CSTB2
proteins migrating as doublets in the SDS-PAGE is not known.
We then studied the subcellular localization of overexpressed CSTB2 using
immunofluorescence analysis with the polyclonal CSTB antibody. First, the
overexpressed CSTB protein was shown to localize with the polyclonal CSTB
antibody (Fig. 13A), similarly to with the monoclonal 2E7 antibody (Fig. 11A; III,
Fig. 5A; IV, Fig. 6A), in the nucleus, cytoplasm and lysosomes. Wild-type (Fig. 13B)
and p.Gly4Arg (Fig. 13C) CSTB2 proteins localized evenly to cytoplasm and nucleus,
while no lysosomal punctate structures were visible. The effect of the p.Gly50Glu
mutation on CSTB2 protein localization was dramatic as it aggregated to the
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cytoplasm or nucleus (Fig. 13D, E). Colocalization with several aggresomal markers
was attempted but no overlap could be visualized (data not shown).
Figure 13. Immunofluorescence analysis of the cellular distribution of wild-type CSTB and CSTB2,
and mutant CSTB2 proteins in transiently transfected BHK cells immunostained with the polyclonal
CSTB antibody. (A) CSTB localizes to nucleus, lysosomes and cytoplasm. Wild-type (B) and
p.Gly4Arg (C) CSTB2 proteins localize evenly to cytoplasm and nucleus. p.Gly50Glu mutant CSTB2
protein aggregates to cytoplasm (D) or nucleus (E) (unpublished).
In conclusion, the existence of endogenous CSTB2 protein could not be
proven, while the overexpressed CSTB2 protein was stable and localized to cytoplasm
and nucleus, but not to lysosomes. Whether CSTB2 is translated in vivo remains
unknown. The CSTB2 transcript is observed in multiple expressed sequence tags
(ESTs) from cDNA libraries implying that it has physiological relevance. Moreover,
it is also present in mouse EST databases. CSTB2 is spliced following the GT-AG rule
and is conserved among humans and mice. The mRNA expression of CSTB2 and
Cstb2 was detected at very low levels with various methods. CSTB2 could have a
regulatory function on CSTB expression at the post-transcriptional level by inhibiting
the splicing of the pre-mRNA or by representing a storage form of the immature
transcript. It also remains possible that it is translated into a protein that has distinct
functions from that of CSTB. EPM1 patients also had similarly decreased expression
of CSTB2 than that of CSTB. The relevance of this ubiquitously expressed CSTB2
transcript in normal physiological and EPM1 pathological conditions remains to be
investigated.
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CONCLUSIONS AND FUTURE PROSPECTS
The work aim within our research group is understanding the molecular pathogenetic
mechanisms that underlie the progressive myoclonus epilepsy of Unverricht-
Lundborg type (EPM1) caused by mutations in the CSTB gene. CSTB, a cysteine
protease inhibitor, has been considered to inhibit inappropriate proteolysis due to
cathepsins that leak out of the lysosomes, but its physiological function is still
unknown. In this study, the CSTB gene was characterized, and expression and
localization studies of CSTB mRNA and protein were initiated.
The CSTB promoter was shown to have a typical housekeeping gene promoter
sequence and to contain several active transcriptional binding sites. However, Cstb
was shown to be widely expressed throughout mouse embryonic development albeit
with tight temporal regulation and a restricted tissue and cellular expression pattern.
Cstb expression was highest in E7 embryos and in epithelial layers of several tissues
outside the nervous system even though no developmental or consistent non-neuronal
phenotypes have been detected in EPM1 patients or the Cstb-deficient mouse model.
This suggests that the Cstb inhibitory activity is functionally redundant during
development and in most tissues, compatible with Cstb being a member of a large
family of cysteine protease inhibitors. The high Cstb expression in thymus is
intriguing in light of the suggested function of cathepsins in immune response and the
proposed role of the leech CSTB homologue in innate immunity. The limited cellular
distribution of Cstb in the CNS is in accordance with the clinical presentation and
limited neuronal pathology detected in EPM1 patients and the Cstb-deficient mouse.
It is crucial to continue the investigations of Cstb protein expression in the CNS, the
major organ affected in EPM1, as well as its neuronal metabolism. The Cstb-deficient
mouse provides an excellent model for studying the function of Cstb in in vivo
situations. To continue the investigations a specific antibody for the mouse Cstb
protein is needed.
The lysosomal localization of CSTB demonstrated in this study is compatible
with the current view of CSTB having a protective role as a constitutive cytoplasmic
inhibitor for cysteine proteases released from lysosomes. Whether the lysosomal
association is due to cathepsin interaction, which would be suggested based on our
localization studies with mutant CSTB proteins, remains to be further studied. This
hypothesis is supported by the decreased cerebellar granule cell apoptosis detected in
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mice doubly deficient for Cstb and Ctsb. The ataxia and seizure phenotypes in these
mice were not dimished, suggesting that CSTB might have functions other than
inhibition of cathepsins. CSTB localized also to cytoplasm and nucleus, suggesting
that it could also function for example in signaling events involved in apoptosis with
downstream effects on transcriptional regulation. CSTB localization was also
dependent on the differentiation status of the cells, as the subcellular distribution of
the CSTB was altered upon cell differentiation. The distribution of CSTB should be
determined in several cell types under different conditions, especially in neuronal
cells.
The repeat expansion decreased the CSTB  promoter activity in vitro,
concordantly significantly reduced amounts of CSTB mRNA and protein were
detected in patient cells. In line with this, as the expansion mutation significantly
reduces the amount of CSTB protein capable of inhibiting cathepsins, cathepsins B, L
and S activities are increased. In addition to the repeat expansion mutation, the other
EPM1 mutations were also shown to decrease in vivo the CSTB mRNA and/or protein
levels. All mutant proteins lost lysosomal association, highlighting the importance of
this association for the normal physiological and pathological function of CSTB. It
remains speculative if this association is a consequence of altered cathepsin inhibitory
function.
The CSTB gene was shown to be alternatively spliced, but the physiological
relevance of this remains unknown.
More studies have to be conducted to clarify the cellular function of CSTB
and the related molecular mechanism of neuronal survival and function, as well as the
molecular pathogenesis of EPM1. Understanding the normal physiological and
pathogenetic mechanism of CSTB will be essential for the discovery of new drugs
and better treatment methods for EPM1 in the future.
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